sign in sign up
<<
Home , Anagrelide, Bexarotene, Cabazitaxel, Cabozantinib, Carfilzomib, Chlormethine

Page 1 of 65 BC Benefit Drug List September 2021

DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected]

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES for Metastatic Castration-Sensitive using abiraterone Genitourinary UGUMCSPABI* R Abiraterone and Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone capsule reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal -positive tablet Lung LUAVAFAT I advanced non-small cell with afatinib aldesleukin injectable Skin & Treatment of In-Transit Melanoma with Intralesional Aldesleukin IL-2 SMILALD I pediatric patients with high risk treated on the ANBL0032 aldesleukin injectable Pediatric I study treatment of pediatric patients with high-risk neuroblastoma who achieve aldesleukin injectable Pediatric a response to prior first-line multi-agent, multimodal therapy using R in combination with , aldesleukin and treatment of ALK-positive advanced non-small cell lung cancer with capsule Lung LUAVALE I alectinib treatment of -refractory B-chronic lymphocytic and T- injectable Lymphoma LYALEM I prolymphocytic leukemia Only reimbursable when prescribed by physicians in the topical solution Skin & Melanoma topical therapy for skin cancer with PDT () SMPDT I (LEVULAN® KERASTICK®) Skin Tumour Group within the BC Cancer Skin PDT Program injectable Leukemia & BMT LKNOS I patients with thrombocytosis related to a myeloproliferative disorder who capsule Leukemia & BMT have had an inadequate response to or are intolerant of hydroxyurea LKANAG I and/or interferon neoadjuvant or adjuvant therapy for using in anastrozole tablet Breast BRAJANAS I postmenopausal women neoadjuvant or adjuvant ovarian suppression and in anastrozole tablet Breast BRAJLHRHAI I premenopausal women with high-risk early stage breast cancer first or second line hormonal treatment for advanced breast cancer in anastrozole tablet Breast BRAVANAS I postmenopausal women therapy for advanced breast cancer using a LHRH agonist and an anastrozole tablet Breast BRAVLHRHA I aromatase inhibitor therapy of advanced breast cancer using and aromatase anastrozole (cont'd) tablet Breast UBRAVPALAI I inhibitor with or without LHRH agonist therapy of advanced breast cancer using and aromatase anastrozole anastrozole Breast UBRAVRIBAI R inhibitor with or without LHRH agonist

* denotes change Page 2 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES hormonal treatment for advanced in postmenopausal anastrozole (cont'd) tablet Gynecology GOENDAI I women with contraindications to or intolerant of tamoxifen

anastrozole (cont'd) tablet Gynecology therapy for advanced using an aromatase inhibitor GOOVAI I therapy of non-metastatic castration-resistant prostate cancer using apalutamide tablet Genitourinary UGUPAPA R apalutamide first-line induction and consolidation therapy of acute promyelocytic injectable Leukemia & BMT LKATOATRA I leukemia using arsenic trioxide and tretinoin first-line induction and consolidation therapy of acute promyelocytic arsenic trioxide injectable Leukemia & BMT LKATOP I leukemia using arsenic trioxide, tretinoin and induction and consolidation therapy of relapsed acute promyelocytic arsenic trioxide injectable Leukemia & BMT LKATOR I leukemia using arsenic trioxide and tretinoin (All-Trans ) injectable Leukemia & BMT LKNOS, LYNOS I (KIDROLASE®) treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma asparaginase-erwinia injectable Leukemia & BMT using asparaginase-Erwinia (Erwinase®) in patients allergic to LKNOS, LYNOS I (ERWINASE®) asparaginase (Kidrolase®) or (Oncaspar®) injectable Lung treatment of advanced non-small cell lung cancer LUAVATZ I treatment of advanced non-small cell lung cancer using 4-weekly atezolizumab injectable Lung LUAVATZ4 I atezolizumab second-line treatment of recurrent or metastatic merkel cell injectable Skin & Melanoma SMMCCAVE I using avelumab tablet Genitourinary therapy for metastatic using axitinib GUAXIT I Treatment of Metastatic Renal Cell Carcinoma Using and axitinib tablet Genitourinary GUAVPEMAX I Axitinib injectable Leukemia & BMT therapy of using azacitidine and LKAMLAS I azacitidine (cont'd) injectable Leukemia & BMT therapy of myelodysplastic syndrome ULKMDSA R bacillus calmette guerin The three substrains of BCG available injectable Genitourinary therapy for high risk superficial transitional cell GUBCG I (BCG) are considered interchangeable by BC Cancer for the treatment of bladder cancer (i.e., Montreal [PACIS] 120 mg bacillus calmette guerin palliative therapy for BCG-refractory superficial high-grade transitional = TICE [OncoTICE] 1 to 8 x 108 CFU injectable Genitourinary GUBCGIFN I (BCG) (cont'd) cell carcinoma bladder with BCG and Interferon = Connaught [ImmuCyst] 81 mg) BUT only the current contract brand is reimbursed at the current contract price injectable Lymphoma treatment of Non- with bendamustine LYBEND I bendamustine (cont'd) injectable Lymphoma treatment of Non-Hodgkin Lymphoma with bendamustine and LYBENDR I bendamustine injectable Lymphoma treatment of relapsed chronic lymphocytic leukemia with bendamustine LYCLLBEND I treatment of relapsed/refractory chronic lymphocytic leukemia or small bendamustine injectable Lymphoma LYCLLBENDR I lymphocytic lymphoma with bendamustine and rituximab treatment of previously untreated chronic lymphocytic leukemia (CLL) bendamustine (cont'd) injectable Lymphoma LYCLLFBR I with bendamustine and rituximab treatment of rituximab-refractory with bendamustine injectable Lymphoma LYOBBEND I in combination with bendamustine

* denotes change Page 3 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES palliative therapy of metastatic using and injectable Gastrointestinal GIAVCAPB I bevacizumab palliative combination chemotherapy for metastatic colorectal cancer bevacizumab injectable Gastrointestinal GICIRB I using , bevacizumab and capecitabine palliative combination chemotherapy for metastatic colorectal cancer bevacizumab injectable Gastrointestinal GICOXB I using , bevacizumab and capecitabine palliative combination chemotherapy for metastatic colorectal cancer bevacizumab (cont'd) injectable Gastrointestinal GIFFIRB I using irinotecan, , (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer bevacizumab (cont'd) injectable Gastrointestinal GIFFOXB I using oxaliplatin, fluorouracil, leucovorin, and bevacizumab bevacizumab (cont'd) injectable Neuro-Oncology patients with relapsed malignant gliomas CNBEV I alternative treatment of gynecological malignancies using bevacizumab, bevacizumab (cont'd) injectable Gynecology GOCABRBEV I and NAB (ABRAXANE) Alternative Treatment of Gynecological Malignancies using Note: Biosimilar bevacizumab bevacizumab (cont'd) injectable Gynecology GOCISPBEV I Bevacizumab, and Paclitaxel (ZIRABEV®, MVASI®) is funded primary treatment of metastatic/recurrent cancer of the cervix with bevacizumab (cont'd) injectable Gynecology GOCXCATB I for treatment started on or after bevacizumab, carboplatin and paclitaxel treatment of resistant epithelial ovarian cancer with November 1st, 2019. AVASTIN® bevacizumab (cont'd) injectable Gynecology GOOVBEVG I bevacizumab and is funded for treatment started treatment of platinum resistant epithelial ovarian cancer with prior to November 1st, 2019. bevacizumab injectable Gynecology GOOVBEVLD I bevacizumab and pegylated liposomal treatment of platinum resistant epithelial ovarian cancer with bevacizumab (cont'd) injectable Gynecology GOOVBEVP I bevacizumab and paclitaxel treatment of platinum resistant epithelial ovarian cancer with bevacizumab injectable Gynecology GOOVBEVV I bevacizumab and primary treatment of invasive epithelial ovarian, fallopian tube and bevacizumab (cont'd) injectable Gynecology primary peritoneal cancer with high risk of relapse using bevacizumab, GOOVCATB I carboplatin and paclitaxel treatment with bevacizumab as a single agent or in combination with bevacizumab (cont'd) Pediatric chemotherapy for pediatric patients with low-grade gliom progressing I after first-line chemotherapy therapy for advanced solitary fibrous tumours and hemangiopericytoma bevacizumab (cont'd) SATEMBEV I using and bevacizumab Approval from Health Canada (SAP) capsule Lymphoma patients with refractory cutaneous T-cell lymphoma LYMFBEX I Special Access Programme is required for each patient. Not reimbursed for vasomotor tablet Genitourinary nonsteroidal treatment of prostate cancer, at 50 mg po daily GUPNSAA I symptoms (hot flashes) or high dose monotherapy therapy of non-dysgerminomatous ovarian germ cell cancer using injectable Gynecology GOBEP I bleomycin, , and cisplatin curative therapy for germ cell cancer using with bleomycin, etoposide, bleomycin injectable Genitourinary GUBEP I Not reimbursed for pleurodesis cisplatin for germ cell palliative therapy for kaposi’s sarcoma using alternating with bleomycin injectable Kaposi's Sarcoma KSVB I

* denotes change Page 4 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of Hodgkin lymphoma with doxorubicin, bleomycin, vinblastine, bleomycin (cont'd) injectable Lymphoma LYABVD I and treatment of Hodgkin's Disease with , vinblastine, bleomycin injectable Lymphoma LYCVPPABO I Not reimbursed for pleurodesis and prednisone Other tumour site code Not Otherwise bleomycin injectable followed by ‘NOS’ (e.g. I Specified LYNOS) treatment of (Ph)-positive or Ph-negative injectable Leukemia & BMT refractory or relapsed pre-B-cell acute lymphoblastic leukemia with ULKBLIN R blinatumomab treatment of pediatric patients with Philadelphia chromosome-negative blinatumomab injectable Leukemia & BMT (Ph-) relapsed or refractory pre-B-cell acute lymphoblastic leukemia R using blinatumomab , and for Previously Untreated bortezomib injectable Myeloma UMYBLDF R maintenance therapy for multiple myeloma using bortezomib for patients bortezomib injectable Myeloma MYBORMTN I with the high-risk chromosome abnormality treatment of multiple myeloma using bortezomib, dexamethasone with or injectable Myeloma MYBORPRE I without cyclophosphamide as induction pre-stem cell transplant treatment of relapsed multiple myeloma using bortezomib, bortezomib injectable Myeloma MYBORREL I dexamethasone with or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with bortezomib (cont'd) injectable Myeloma in combination with bortezomib and dexamethasone with UMYDARBD R or without cyclophosphamide treatment of multiple myeloma using , prednisone and weekly bortezomib (cont'd) injectable Myeloma bortezomib with the option of substituting cyclophosphamide for MYMPBOR I melphalan tablet Leukemia & BMT treatment of chronic myeloid leukemia using bosutinib LKCMLB I Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with injectable Lymphoma LYAVDBV I Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin treatment of Hodgkin lymphoma and anaplastic large cell lymphoma with brentuximab vedotin injectable Lymphoma LYBRENTUX I brentuximab vedotin treatment for consolidation therapy post-autologous stem cell transplant brentuximab vedotin injectable Lymphoma LYBV I (ASCT) for Hodgkin lymphoma using brentuximab vedotin treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with brentuximab vedotin (cont'd) injectable Lymphoma doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab LYCHPBV I vedotin Treatment of Cutaneous T-Cell Lymphoma (CTCL) with Brentuximab brentuximab vedotin injectable Lymphoma LYCTCLBV I Vedotin bromocriptine tablet, capsule Neuro-Oncology therapy for pituitary adenomas using bromocriptine CNB I

* denotes change Page 5 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES long-acting neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in buserelin Breast BRAJLHRHAI I injectable premenopausal women with high-risk early stage breast cancer neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist buserelin (cont'd) injectable Breast BRAJLHRHT I and tamoxifen therapy for advanced breast cancer using a LHRH agonist and an buserelin injectable Breast BRAVLHRHA I aromatase inhibitor combination therapy with tamoxifen as palliative therapy for metastatic buserelin injectable Breast BRAVLHRHT I breast cancer therapy of advanced breast cancer using palbociclib and aromatase Not reimbursed for endometriosis buserelin injectable Breast UBRAVPALAI R inhibitor with or without LHRH agonist Therapy of Advanced Breast Cancer using Palbociclib and buserelin injectable Breast UBRAVPBFLV R with or without LHRH Agonist Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant buserelin injectable Breast UBRAVRBFLV R with or without LHRH Agonist therapy of advanced breast cancer using ribociclib and aromatase buserelin injectable Breast UBRAVRIBAI R inhibitor with or without LHRH agonist buserelin (cont'd) injectable Genitourinary therapy for prostate cancer using LHRH agonist GUPLHRH I Tumour site code Not Otherwise tablet followed by ‘NOS’ I Specified (e.g. LKNOS) myeloablative conditioning therapy prior to hematopoietic stem cell busulfan injectable Leukemia & BMT BMTIVBUCY I transplantation for myeloid malignancies busulfan injectable Pediatric pediatric patients who cannot swallow oral busulfan I palliative therapy for metastatic castration resistant prostate cancer using injectable Genitourinary GUPCABA I cabazitaxel and prednisone cabergoline tablet Neuro-Oncology therapy for pituitary adenomas using cabergoline CNCAB I tablet Genitourinary therapy for metastatic renal cell carcinoma using cabozantinib GUCABO I

* denotes change Page 6 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES capecitabine tablet Breast therapy of adjuvant breast cancer using capecitabine BRAJCAP I as first line treatment if and contraindicated, or where sidfect profile and/or treatment capecitabine (cont'd) tablet Breast delivery concerns favour initial use of BRAVCAP; second or third line BRAVCAP I treatment of metastatic breast cancer that has previously responded to an and capecitabine tablet Breast therapy for metastatic breast cancer using capecitabine and BRAVLCAP I palliative therapy for metastatic breast cancer using and capecitabine tablet Breast BRAVTCAP I capecitabine capecitabine tablet Gastrointestinal adjuvant therapy of colon cancer using capecitabine GIAJCAP I adjuvant combination chemotherapy for stage III and IIB colon cancer capecitabine tablet Gastrointestinal GIAJCAPOX I with oxaliplatin first line palliative therapy of metastatic or unresectable colorectal capecitabine (cont'd) tablet Gastrointestinal GIAVCAP I in a patient either not suitable for or refusing GIIRFUFA palliative therapy of metastatic colorectal cancer using capecitabine and capecitabine (cont'd) tablet Gastrointestinal GIAVCAPB I bevacizumab combined modality therapy for metastatic rectal carcinoma using capecitabine tablet Gastrointestinal GIAVCRT I capecitabine and palliative therapy of metastatic neuroendocrine cancer using capecitabine tablet Gastrointestinal GIAVTZCAP I temozolomide and capecitabine capecitabine (cont'd) tablet Gastrointestinal Adjuvant Therapy of Biliary Cancer using Capecitabine GIBAJCAP I palliative combination chemotherapy for metastatic colorectal cancer capecitabine (cont'd) tablet Gastrointestinal GICAPIRI I using irinotecan and capecitabine in patients unsuitable for GIFOLFIRI palliative combination chemotherapy for metastatic colorectal cancer capecitabine (cont'd) tablet Gastrointestinal GICAPOX I using oxaliplatin and capecitabine combination with mitomycin and radiation therapy as curative combined capecitabine (cont'd) tablet Gastrointestinal GICART I modality therapy for carcinoma of the anal canal palliative combination chemotherapy for metastatic colorectal cancer capecitabine (cont'd) tablet Gastrointestinal GICIRB I using irinotecan, bevacizumab and capecitabine palliative combination chemotherapy for metastatic colorectal cancer capecitabine (cont'd) tablet Gastrointestinal GICOXB I using oxaliplatin, bevacizumab and capecitabine curative-intent combined modality therapy for cancer of the anal canal, capecitabine (cont'd) tablet Gastrointestinal GICPART I using cisplatin, capecitabine and radiation therapy adjuvant chemotherapy in gastric cancer patients with D2 resection capecitabine (cont'd) tablet Gastrointestinal (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin GIGAJCOX I and capecitabine adjuvant chemotherapy in gastric cancer patients with completely capecitabine (cont'd) tablet Gastrointestinal resected gastric cancer using cisplatin and capecitabine and radiation GIGAJCPRT I therapy palliative therapy of metastatic or locally advanced anal squamous cell capecitabine (cont'd) tablet Gastrointestinal GIGAVCC I carcinoma using cisplatin and capecitabine Palliative Treatment of Metastatic or Locally Advanced Gastric, capecitabine (cont'd) tablet Gastrointestinal Gastroesophageal Junction or Esophageal Adenocarcinoma using GIGAVCCT I Cisplatin, Capecitabine and Trastuzumab

* denotes change Page 7 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES palliative treatment of metastatic or locally advanced gastric, capecitabine (cont'd) tablet Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVCOX I capecitabine and oxaliplatin palliative treatment of metastatic or locally advanced gastric, capecitabine (cont'd) tablet Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVCOXT I capecitabine, oxaliplatin and trastuzumab treatment of operable cancer of the stomach, stomach-esophagus capecitabine (cont'd) tablet Gastrointestinal junction or lower 1/3 esophagus, given before and after surgery, using GIGECC I , cisplatin and capecitabine adjuvant chemotherapy for resected pancreatic adenocarcinoma using capecitabine (cont'd) tablet Gastrointestinal GIPAJGCAP I capecitabine and gemcitabine second line treatment of metastatic or unresectable pancreatic capecitabine (cont'd) tablet Gastrointestinal GIPAVCAP I adenocarcinoma using capecitabine Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal capecitabine (cont'd) tablet Gastrointestinal GIRAJCOX I Cancer using Oxaliplatin and Capecitabine adjuvant capecitabine therapy for stage II and III rectal cancer previously capecitabine (cont'd) tablet Gastrointestinal GIRCAP I treated with preoperative radiotherapy combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine (cont'd) tablet Gastrointestinal GIRCRT I capecitabine and radiation therapy combined modality adjuvant therapy for high risk rectal carcinoma using capecitabine (cont'd) tablet Gastrointestinal GIRINFRT I capecitabine, infusional fluorouracil and radiation therapy treatment of recurrent or metastatic squamous cell cancer of the head capecitabine (cont'd) tablet Head and Neck HNAVCAP I and neck with capecitabine treatment of recurrent or metastatic nasopharyngeal cancer with capecitabine (cont'd) tablet Head and Neck HNNAVCAP I capecitabine neoadjuvant or adjuvant therapy for breast cancer using carboplatin, carboplatin injectable Breast BRAJDCARBT I and trastuzumab palliative therapy for metastatic breast cancer using cisplatin and carboplatin (cont'd) injectable Breast BRAVGEMP I gemcitabine neoadjuvant therapy for triple-negative breast cancer using carboplatin carboplatin (cont'd) injectable Breast BRLACTWAC I and weekly paclitaxel followed by doxorubicin and cyclophosphamide Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose- carboplatin (cont'd) injectable Breast Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by BRLACTWACG I Doxorubicin and Cyclophosphamide carboplatin injectable Neuro-Oncology carboplatin and etoposide in the treatment of recurrent ependymoma CNCARV I First-Line Palliative Treatment of Metastatic Anal Squamous Cell carboplatin (cont'd) injectable Gastrointestinal GIAAVCT I Carcinoma using Carboplatin and Weekly Paclitaxel first-line palliative chemotherapy for advanced gallbladder cancer and carboplatin (cont'd) injectable Gastrointestinal GIAVPG I using gemcitabine and cisplatin neoadjuvant treatment of esophageal and gastroesophageal carboplatin injectable Gastrointestinal GIENACTRT I using carboplatin, paclitaxel and radiation therapy alternative treatment of gynecological malignancies using carboplatin and carboplatin (cont'd) injectable Gynecology GOCABR I paclitaxel NAB (ABRAXANE) alternative treatment of gynecological malignancies using bevacizumab, carboplatin (cont'd) injectable Gynecology GOCABRBEV I carboplatin and paclitaxel NAB (ABRAXANE) primary adjuvant treatment of adenocarcinoma/adenosquamous cancer carboplatin (cont'd) injectable Gynecology of the cervix with carboplatin and paclitaxel preceding or following GOCXAJCAT I irradiation with or without cisplatin

* denotes change Page 8 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of advanced/recurrent non-small cell cancer of the cervix with carboplatin (cont'd) injectable Gynecology GOCXCAD I carboplatin and docetaxel primary treatment of advanced/recurrent non-small cell cancer of the carboplatin (cont'd) injectable Gynecology GOCXCAT I cervix with carboplatin and paclitaxel primary treatment of metastatic/recurrent cancer of the cervix with carboplatin injectable Gynecology GOCXCATB I bevacizumab, carboplatin and paclitaxel treatment of primarily advanced or recurrent endometrial cancer using carboplatin injectable Gynecology GOENDCAD I carboplatin and docetaxel treatment of primary advanced or recurrent endometrial cancer using carboplatin (cont'd) injectable Gynecology GOENDCAT I carboplatin and paclitaxel primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial carboplatin (cont'd) injectable Gynecology GOOVCAD I ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel carboplatin and gemcitabine for the treatment of recurrent platinum- carboplatin (cont'd) injectable Gynecology GOOVCAG I sensitive ovarian cancer first or second line therapy for invasive epithelial ovarian cancer using carboplatin (cont'd) injectable Gynecology GOOVCARB I single-agent carboplatin primary treatment of invasive epithelial ovarian, fallopian tube and carboplatin (cont'd) injectable Gynecology primary peritoneal cancer with high risk of relapse using bevacizumab, GOOVCATB I carboplatin and paclitaxel primary treatment of invasive epithelial ovarian, fallopian tube and carboplatin (cont'd) injectable Gynecology primary peritoneal cancer, with no visible residual tumour (moderate-high GOOVCATM I risk) using carboplatin and paclitaxel second line treatment using paclitaxel and carboplatin for epithelial carboplatin (cont'd) injectable Gynecology GOOVCATR I ovarian cancer relapsing after primary treatment primary treatment of visible residual (extreme risk) invasive epithelial carboplatin (cont'd) injectable Gynecology ovarian cancer in ambulatory care settings using paclitaxel and GOOVCATX I carboplatin primary treatment of advanced epithelial ovarian, primary peritoneal, or carboplatin (cont'd) injectable Gynecology GOOVDDCAT I fallopian tube carcinoma using carboplatin and weekly paclitaxel first line treatment of epithelial ovarian cancer using doxorubicin carboplatin (cont'd) injectable Gynecology GOOVFPLDC I pegylated liposomal and carboplatin primary treatment of stage III less than or equal to 1 cm visible residual invasive epithelial ovarian cancer or stage 1 grade 3 or stage II grade 3 carboplatin (cont'd) injectable Gynecology GOOVIPPC I papillary serous ovarian cancer using intravenous and intraperitoneal paclitaxel and intraperitoneal carboplatin second line treatment for epithelial ovarian cancer relapsing after primary carboplatin (cont'd) injectable Gynecology GOOVPLDC I treatment using pegylated liposomal doxorubicin (PLD) and carboplatin

carboplatin (cont'd) injectable Gynecology treatment of small-cell gynecologic cancer with cisplatin and etoposide GOSCPE I treatment of small-cell gynecologic cancer with cisplatin and etoposide carboplatin (cont'd) injectable Gynecology GOSCPERT I with radiation therapy

carboplatin (cont'd) injectable Genitourinary palliative therapy for urothelial carcinoma using cisplatin and gemcitabine GUAVPG I

* denotes change Page 9 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES carboplatin (cont'd) injectable Genitourinary adjuvant therapy for stage I high risk seminoma using carboplatin GUSCARB I carboplatin (cont'd) injectable Genitourinary therapy of genitourinary small cell tumors with a platin and etoposide GUSCPE I therapy of genitourinary small cell tumors with a platin and etoposide with carboplatin (cont'd) injectable Genitourinary GUSCPERT I radiation treatment of advanced squamous cell carcinoma of the head and neck carboplatin (cont'd) injectable Head and Neck HNAVFUP I cancer using fluorouracil and platinum treatment for unresectable, locoregionally recurrent or metastatic carboplatin (cont'd) injectable Head and Neck squamous cell carcinoma of the head and neck using paclitaxel and HNAVPC I cisplatin or carboplatin First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head carboplatin (cont'd) injectable Head and Neck UHNAVPCPMB R and Neck with Paclitaxel, Carboplatin and Pembrolizumab treatment of recurrent or metastatic squamous cell carcinoma of the carboplatin (cont'd) injectable Head and Neck HNAVPD I head and neck with platinum and docetaxel treatment of recurrent and metastatic squamous cell cancer with carboplatin (cont'd) injectable Head and Neck HNAVPE I platinum and etoposide First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head carboplatin (cont'd) injectable Head and Neck UHNAVPFPMB R and Neck using Platinum, Fluorouracil and Pembrolizumab combined chemotherapy (carboplatin and fluorouracil) and radiation carboplatin (cont'd) injectable Head and Neck treatment for locally advanced squamous cell carcinoma of the head and HNLACAFRT I neck treatment of locally advanced squamous cell carcinoma of the head and carboplatin (cont'd) injectable Head and Neck HNLACART I neck with concurrent carboplatin and radiation treatment for advanced nasopharyngeal cancer of the head and neck carboplatin (cont'd) injectable Head and Neck HNNAVFUP I using platinum and fluorouracil treatment of recurrent and/or metastatic nasopharyngeal cancer with carboplatin (cont'd) injectable Head and Neck HNNAVPE I platinum and etoposide treatment of locoregionally recurrent and/or metastatic nasopharyngeal carboplatin (cont'd) injectable Head and Neck HNNAVPG I cancer with platinum and gemcitabine treatment of recurrent or metastatic nasopharyngeal carcinoma with carboplatin (cont'd) injectable Head and Neck HNNAVPC I carboplatin and paclitaxel adjuvant carboplatin and paclitaxel following resection of stage I, II and carboplatin (cont'd) injectable Lung LUAJPC I IIIA non-small cell lung cancer first-line treatment of advanced non-small cell lung cancer with carboplatin (cont'd) injectable Lung LUAVPC I carboplatin and paclitaxel first-line treatment of advanced squamous non-small cell lung cancer carboplatin (cont'd) injectable Lung ULUAVPCPMB R with paclitaxel, carboplatin and pembrolizumab treatment of advanced non-small cell lung cancer with platinum and carboplatin (cont'd) injectable Lung LUAVPG I gemcitabine first-line treatment of advanced squamous non-small cell lung cancer cisplatin (cont'd) injectable Lung ULUAVPGPMB R with platinum, gemcitabine and pembrolizumab first-line treatment of advanced non-small cell lung cancer with platinum carboplatin (cont'd) injectable Lung LUAVPP I and first-line treatment of advanced non-squamous non-small cell lung cancer carboplatin (cont'd) injectable Lung ULUAVPPPMB R with platinum, pemetrexed and pembrolizumab treatment of locally advanced non-small cell lung cancer using carboplatin (cont'd) injectable Lung LULACATRT I carboplatin and paclitaxel with radiation therapy treatment of locally advanced non-small cell lung cancer using cisplatin carboplatin (cont'd) injectable Lung LULAPERT I and etoposide with radiation therapy

* denotes change Page 10 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of locally advanced non-small cell lung cancer using alternative carboplatin (cont'd) injectable Lung LULAPE2RT I dosing of cisplatin and etoposide with radiation therapy carboplatin (cont'd) injectable Lung treatment of thymoma with cisplatin and etoposide LUOTPE I treatment of thymoma using cisplatin and etoposide with radiation carboplatin (cont'd) injectable Lung LUOTPERT I therapy of unknown primary involving the thorax with cisplatin carboplatin (cont'd) injectable Lung LUPUPE I and etoposide therapy of extensive stage small cell lung cancer with cisplatin and carboplatin (cont'd) injectable Lung LUSCPE I etoposide therapy of limited stage small cell lung cancer using cisplatin and carboplatin (cont'd) injectable Lung LUSCPERT I etoposide with radiation second line treatment of extensive stage small cell lung cancer (SCLC) carboplatin (cont'd) injectable Lung LUSCPI I with irinotecan with or without platinum treatment of relapsed or refractory advanced stage aggressive B-cell non- carboplatin (cont'd) injectable Lymphoma Hodgkin’s lymphoma with , carboplatin, etoposide and LYRICE I rituximab primary treatment of cancer of unknown primary origin using carboplatin carboplatin (cont'd) injectable Primary Unknown PUCAT I and paclitaxel treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin carboplatin (cont'd) injectable Skin & Melanoma SMMCCPE I and etoposide Other tumour site Not Otherwise carboplatin (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. HNNOS)

* denotes change Page 11 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES therapy of multiple myeloma using and dexamethasone with carfilzomib injectable Myeloma UMYCARDEX R or without cyclophosphamide therapy of multiple myeloma using carfilzomib, lenalidomide with carfilzomib injectable Myeloma UMYCARLD R dexamethasone injectable Lymphoma topical therapy in cutaneous T-cell lymphoma LYCARTOP I Other tumour site Not Otherwise carmustine injectable code followed by I Specified ‘NOS’ (e.g. LKNOS) injectable Skin & Melanoma Cemiplimab for Treatment of Cutaneous Squamous Cell Carcinoma USMAVCEM R treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) capsule Lung ULUAVCER R with ceritinib palliative third line treatment of metastatic colorectal cancer with wild- injectable Gastrointestinal GIAVCETIR I type KRAS using cetuximab and irinotecan combined cetuximab and radiation treatment for locally advanced cetuximab (cont'd) injectable Head and Neck HNLACETRT I squamous cell carcinoma of the head and neck tablet Lymphoma low grade lymphoma and chronic lymphocytic leukemia LYCHLOR I chlorambucil tablet Lymphoma treatment of indolent B-cell lymphoma with chlorambucil and rituximab LYCHLRR I treatment of chronic lymphocytic leukemia with chlorambucil and chlorambucil tablet Lymphoma LYCLLCHLR I rituximab chlorambucil tablet Lymphoma lymphoma palliative chemotherapy LYPALL I treatment of previously untreated chronic lymphocytic leukemia using chlorambucil (cont'd) tablet Lymphoma LYOBCHLOR I obinutuzumab in combination with chlorambucil Other tumour site Not Otherwise code followed by chlorambucil (cont'd) tablet I Specified ‘NOS’ (e.g. LKNOS, LYNOS)

* denotes change Page 12 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES palliative therapy for metastatic breast cancer using cisplatin and cisplatin injectable Breast BRAVGEMP I gemcitabine adjuvant , cisplatin and vincristine in adult high-risk cisplatin Neuro-Oncology CNCCV I injectable medulloblastoma or other primitive neuroectodermal tumour first-line palliative chemotherapy for advanced gallbladder cancer and cisplatin Gastrointestinal GIAVPG I injectable cholangiocarcinoma using gemcitabine and cisplatin curative-intent combined modality therapy for cancer of the anal canal, cisplatin GICPART I injectable Gastrointestinal using cisplatin, capecitabine and radiation therapy Note: cisplatin solution and cisplatin powder (SAP) only hepatic trans-arterial chemoembolization for primary cancer or liver cisplatin (cont'd) injectable Gastrointestinal GIEMBOL I funded when prescribed by metastasis specialists at BC Cancer VC and Royal Jubilee Hospital palliative chemotherapy for upper cancer (gastric, cisplatin (cont'd) injectable Gastrointestinal esophageal, gall bladder carcinoma and cholangiocarcinoma) and GIFUC I metastatic anal cancer using infusional fluorouracil and cisplatin combined modality curative therapy for carcinoma of the anal canal using cisplatin (cont'd) injectable Gastrointestinal GIFUPART I cisplatin, infusional fluorouracil and radiation therapy adjuvant chemotherapy of gastric cancer patients with completely cisplatin (cont'd) injectable Gastrointestinal resected gastric cancer using cisplatin and capecitabine and radiation GIGAJCPRT I therapy palliative therapy of metastatic or locally advanced anal squamous cell cisplatin (cont'd) injectable Gastrointestinal GIGAVCC I carcinoma using cisplatin and capecitabine Palliative Treatment of Metastatic or Locally Advanced Gastric, cisplatin (cont'd) injectable Gastrointestinal Gastroesophageal Junction or Esophageal Adenocarcinoma using GIGAVCCT I Cisplatin, Capecitabine and Trastuzumab palliative treatment of metastatic or inoperable, locally advanced gastric cisplatin (cont'd) injectable Gastrointestinal or gastroesophageal junction adenocarcinoma using cisplatin, infusional GIGAVCFT I fluorouracil and trastuzumab treatment of operable cancer of the stomach, stomach-esophagus cisplatin (cont'd) injectable Gastrointestinal junction or lower 1/3 esophagus, given before and after surgery, using GIGECC I epirubicin, cisplatin and capecitabine palliative therapy of neuroendocrine tumours using cisplatin and cisplatin (cont'd) injectable Gastrointestinal GIPE I etoposide hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with cisplatin (cont'd) Gastrointestinal GIPMHIPEC I injectable peritoneal using doxorubicin, cisplatin and paclitaxel therapy of non-dysgerminomatous ovarian germ cell cancer using cisplatin (cont'd) injectable Gynecology GOBEP I bleomycin, etoposide and cisplatin alternative treatment of gynecological malignancies using cisplatin and cisplatin (cont'd) injectable Gynecology GOCISP I paclitaxel

* denotes change Page 13 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Alternative Treatment of Gynecological Malignancies using cisplatin (cont'd) injectable Gynecology GOCISPBEV I Bevacizumab, Cisplatin and Paclitaxel treatment of high risk squamous carcinoma, adenocarcinoma, or cisplatin (cont'd) injectable Gynecology adenosquamous carcinoma of the cervix with concurrent cisplatin and GOCXCRT I radiation therapy of dysgerminomatous ovarian germ cell cancer using cisplatin cisplatin (cont'd) injectable Gynecology GOEP I and etoposide cisplatin (cont'd) injectable Gynecology invasive epithelial ovarian cancer GOOVCIS I cisplatin (cont'd) injectable Gynecology treatment of small-cell gynecologic cancer with cisplatin and etoposide GOSCPE I treatment of small-cell gynecologic cancer with cisplatin and etoposide cisplatin (cont'd) injectable Gynecology GOSCPERT I with radiation therapy

cisplatin (cont'd) injectable Genitourinary adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine GUAJPG I

cisplatin (cont'd) injectable Genitourinary palliative therapy for urothelial carcinoma using cisplatin and gemcitabine GUAVPG I

curative therapy for germ cell cancer using bleomycin, etoposide and cisplatin (cont'd) injectable Genitourinary GUBEP I cisplatin treatment of locally advanced bladder cancer with weekly cisplatin and cisplatin (cont'd) injectable Genitourinary GUBPWRT I concurrent radiation treatment of metastatic adrenalcortical cancer with doxorubicin, cisplatin (cont'd) injectable Genitourinary GUEDPM I etoposide, cisplatin and cisplatin (cont'd) injectable Genitourinary therapy for nonseminoma germ cell cancer using etoposide-cisplatin GUEP I combined modality therapy for squamous cell cancer of the genitourinary cisplatin (cont'd) injectable Genitourinary GUFUPRT I system using fluorouracil and cisplatin with radiation therapy for transitional cell cancers of the urothelium using , cisplatin (cont'd) injectable Genitourinary GUMVAC I vinblastine, doxorubicin and cisplatin neo-adjuvant therapy for urothelial carcinoma using cisplatin and cisplatin (cont'd) injectable Genitourinary GUNAJPG I gemcitabine cisplatin (cont'd) injectable Genitourinary therapy of genitourinary small cell tumors with a platin and etoposide GUSCPE I therapy of genitourinary small cell tumors with a platin and etoposide with cisplatin (cont'd) injectable Genitourinary GUSCPERT I radiation advanced therapy for relapsed testicular germ cell cancer using cisplatin (cont'd) injectable Genitourinary GUTIP I paclitaxel, ifosfamide and cisplatin consolidation/ salvage treatment for germ cell cancer using vinblastine, cisplatin (cont'd) injectable Genitourinary GUVEIP I cisplatin, ifosfamide and nonseminoma consolidation/salvage protocol using etoposide, cisplatin, cisplatin (cont'd) injectable Genitourinary GUVIP2 I ifosfamide, mesna treatment of advanced squamous cell carcinoma of the head and neck cisplatin (cont'd) injectable Head and Neck HNAVFUP I cancer using fluorouracil and platinum palliative chemotherapy for advanced head and neck squamous cell cisplatin (cont'd) injectable Head and Neck HNAVP I carcinoma with weekly cisplatin treatment for unresectable, locoregionally recurrent or metastatic cisplatin (cont'd) injectable Head and Neck squamous cell carcinoma of the head and neck using paclitaxel and HNAVPC I cisplatin or carboplatin

* denotes change Page 14 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of recurrent or metastatic squamous cell carcinoma of the cisplatin (cont'd) injectable Head and Neck HNAVPD I head and neck with platinum and docetaxel treatment of recurrent and metastatic squamous cell cancer with cisplatin (cont'd) injectable Head and Neck HNAVPE I platinum and etoposide First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head cisplatin (cont'd) injectable Head and Neck UHNAVPFPMB R and Neck using Platinum, Fluorouracil and Pembrolizumab treatment of locally advanced (alternate) using cisplatin (cont'd) injectable Head and Neck HNLAALTPRT I cisplatin during radiation therapy treatment of locally advanced squamous cell carcinoma of the head and cisplatin (cont'd) injectable Head and Neck HNLADCF I neck with docetaxel, cisplatin and infusional fluorouracil combined chemotherapy (cisplatin) and radiation treatment for locally cisplatin (cont'd) injectable Head and Neck HNLAPRT I advanced squamous cell carcinoma of the head and neck treatment for advanced nasopharyngeal cancer of the head and neck cisplatin (cont'd) injectable Head and Neck HNNAVFUP I using platinum and fluorouracil palliative chemotherapy for advanced head and neck nasopharyngeal cisplatin (cont'd) injectable Head and Neck HNNAVP I carcinoma with weekly cisplatin treatment of recurrent and/or metastatic nasopharyngeal cancer with cisplatin (cont'd) injectable Head and Neck HNNAVPE I platinum and etoposide treatment of locoregionally recurrent and/or metastatic nasopharyngeal cisplatin (cont'd) injectable Head and Neck HNNAVPG I cancer with platinum and gemcitabine induction treatment of locally advanced nasopharyngeal cancer with cisplatin (cont'd) injectable Head and Neck HNNLAPG I cisplatin and gemcitabine treatment of locally advanced nasopharyngeal cancer with concurrent cisplatin (cont'd) injectable Head and Neck HNNLAPRT I cisplatin and radiation treatment of advanced head and neck cancer using cisplatin and cisplatin (cont'd) injectable Head and Neck HNSAVFUP I fluorouracil treatment of advanced salivary gland cancers with cisplatin and cisplatin (cont'd) injectable Head and Neck HNSAVNP I vinorelbine treatment of advanced salivary gland cancers with platinum, doxorubicin cisplatin (cont'd) injectable Head and Neck HNSAVPAC I and cyclophospahmide adjuvant cisplatin and vinorelbine following resection of non-small cell cisplatin (cont'd) injectable Lung LUAJNP I lung cancer first-line treatment of advanced non-small cell lung cancer with cisplatin cisplatin (cont'd) injectable Lung LUAVDC I and docetaxel treatment for advanced non-small cell lung cancer with cisplatin and cisplatin (cont'd) injectable Lung LUAVNP I vinorelbine treatment of advanced non-small cell lung cancer with platinum and cisplatin (cont'd) injectable Lung LUAVPG I gemcitabine first-line treatment of advanced squamous non-small cell lung cancer cisplatin (cont'd) injectable Lung ULUAVPGPMB R with platinum, gemcitabine and pembrolizumab first-line treatment of advanced non-small cell lung cancer with platinum cisplatin (cont'd) injectable Lung LUAVPP I and pemetrexed first-line treatment of advanced non-squamous non-small cell lung cancer cisplatin (cont'd) injectable Lung ULUAVPPPMB R with platinum, pemetrexed and pembrolizumab treatment of locally advanced non-small cell lung cancer using cisplatin cisplatin (cont'd) injectable Lung LULAPERT I and etoposide with radiation therapy

* denotes change Page 15 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of locally advanced non-small cell lung cancer using alternative cisplatin (cont'd) injectable Lung LULAPE2RT I dosing of cisplatin and etoposide with radiation therapy cisplatin (cont'd) injectable Lung treatment of malignant mesothelioma with platinum and gemcitabine LUMMPG I cisplatin (cont'd) injectable Lung treatment of malignant mesothelioma with platinum and pemetrexed LUMMPP I

cisplatin (cont'd) injectable Lung treatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTPAC I

cisplatin (cont'd) injectable Lung treatment of thymoma with cisplatin and etoposide LUOTPE I treatment of thymoma using cisplatin and etoposide with radiation cisplatin (cont'd) injectable Lung LUOTPERT I therapy treatment of cancer of unknown primary involving the thorax with cisplatin cisplatin (cont'd) injectable Lung LUPUPE I and etoposide therapy of extensive stage small cell lung cancer with cisplatin and cisplatin (cont'd) injectable Lung LUSCPE I etoposide therapy of limited stage small cell lung cancer using cisplatin and cisplatin (cont'd) injectable Lung LUSCPERT I etoposide with radiation second line treatment of extensive stage small cell lung cancer (SCLC) cisplatin (cont'd) injectable Lung LUSCPI I with irinotecan with or without platinum cisplatin (cont'd) injectable Lymphoma treatment of lymphoma with gemcitabine, dexamethasone and platinum LYGDP I treatment of lymphoma with gemcitabine, dexamethasone and platinum cisplatin (cont'd) injectable Lymphoma LYGDPR I with rituximab Treatment of newly diagnosed nasal, extranodal natural killer (NK) or T- cisplatin (cont'd) injectable Lymphoma cell lymphoma, stage IE to IIE using concurrent radiation and weekly LYVIPDRT I cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone cisplatin (cont'd) injectable Sarcoma adjuvant therapy for using doxorubicin and cisplatin SAAJAP I cisplatin (cont'd) injectable Sarcoma therapy of advanced osteosarcoma using doxorubicin and cisplatin SAAVAP I

hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with cisplatin (cont'd) injectable Sarcoma SAHIPEC I peritoneal desmoplastic small round cell tumour (DSRCT) using CISplatin treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin cisplatin (cont'd) injectable Skin & Melanoma SMMCCPE I and etoposide Other tumour site Not Otherwise cisplatin (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. HNNOS) injectable Lymphoma hairy cell leukemia LYCDA I bony metastases associated with breast cancer or acute bone pain clodronate capsule Breast BRAVCLOD I Not reimbursed for hypercalcemia secondary to metastatic breast cancer treatment of BRAF V600 mutation-positive unresectable or metastatic tablet Skin & Melanoma SMAVVC I melanoma using and cobimetinib treatment of metastatic adrenalcortical cancer with doxorubicin, tablet Genitourinary GUEDPM I etoposide, cisplatin and mitotane cortisone tablet Genitourinary treatment of adrenal cortical cancer using mitotane GUMITO I Other tumour site Not Otherwise cortisone tablet code followed by I Specified ‘NOS’ (e.g. GUNOS)

* denotes change Page 16 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES second-line treatment of ALK-positive advanced non-small cell lung tablet Lung LUAVCRIZ I cancer (NSCLC) with crizotinib first-line treatment of ALK-positive advanced non-small cell lung cancer crizotinib (cont'd) tablet Lung LUAVCRIZF I (NSCLC) with crizotinib first-line treatment of ROS1-positive advanced non-small cell lung cancer crizotinib (cont'd) tablet Lung LUAVCRIZR I with crizotinib myeloablative conditioning therapy prior to autologous and allogeneic cyclophosphamide tablet, injectable Leukemia & BMT hematopoietic stem cell transplantation for myeloid malignancies using IV BMTIVBUCY I busulfan and cyclophosphamide adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide tablet, injectable Breast BRAJAC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRAJACT I cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using dose dense cyclophosphamide (cont'd) tablet, injectable Breast BRAJACTG I therapy: doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRAJACTT I cyclophosphamide followed by paclitaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using dose dense cyclophosphamide tablet, injectable Breast therapy: doxorubicin and cyclophosphamide followed by paclitaxel and BRAJACTTG I trastuzumab neoadjuvant or adjuvant therapy for early breast cancer using cyclophosphamide (cont'd) tablet, injectable Breast BRAJACTW I doxorubicin and cyclophosphamide followed by weekly paclitaxel adjuvant therapy for high-risk breast cancer using cyclophosphamide cyclophosphamide (cont'd) tablet, injectable BRAJCMFPO I Breast (oral), methotrexate and fluorouracil neoadjuvant or adjuvant therapy for breast cancer using cyclophosphamide (cont'd) tablet, injectable BRAJDAC I Breast cyclophosphamide, doxorubicin and docetaxel neoadjuvant or adjuvant therapy for breast cancer using docetaxel and cyclophosphamide (cont'd) tablet, injectable Breast BRAJDC I cyclophosphamide adjuvant therapy for breast cancer using fluorouracil, epirubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRAJFEC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, cyclophosphamide (cont'd) tablet, injectable Breast BRAJFECD I epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, cyclophosphamide (cont'd) tablet, injectable BRAJFECDT I Breast epirubicin and cyclophosphamide followed by docetaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, cyclophosphamide (cont'd) tablet, injectable Breast BRAJTDC I docetaxel and cyclophosphamide palliative therapy for metastatic breast cancer using doxorubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRAVAC I cyclophosphamide palliative therapy for advanced breast cancer using cyclophosphamide, cyclophosphamide (cont'd) tablet, injectable BRAVCMF I Breast methotrexate and fluorouracil palliative therapy for metastatic breast cancer using metronomic low- cyclophosphamide (cont'd) tablet, injectable Breast BRAVCMPO I dose oral cyclophosphamide and methotrexate treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRLAACD I cyclophosphamide followed by docetaxel

* denotes change Page 17 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide (cont'd) tablet, injectable Breast BRLAACDT I cyclophosphamide followed by docetaxel and trastuzumab neoadjuvant therapy for triple-negative breast cancer using carboplatin cyclophosphamide (cont'd) injectable Breast BRLACTWAC I and weekly paclitaxel followed by doxorubicin and cyclophosphamide Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose- cyclophosphamide (cont'd) injectable Breast Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by BRLACTWACG I Doxorubicin and Cyclophosphamide neoadjuvant therapy for breast cancer using dose dense therapy: cyclophosphamide (cont'd) injectable Breast BRLATACG I paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and cyclophosphamide (cont'd) injectable Breast BRLATWAC I cyclophosphamide followed by weekly paclitaxel palliative therapy for relapsed/progressing epithelial ovarian, primary cyclophosphamide (cont'd) tablet, injectable Gynecology peritoneal, or fallopian tube carcinoma using metronomic low-dose oral GOOVCYCPO I cyclophosphamide therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using cyclophosphamide (cont'd) tablet, injectable Gynecology etoposide, methotrexate, leucovorin (folinic acid), , GOTDEMACO I cyclophosphamide and vincristine palliative therapy for advanced salivary gland cancers using cyclophosphamide (cont'd) tablet, injectable Head and Neck HNSAVFAC I cyclophosphamide, doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin cyclophosphamide (cont'd) tablet, injectable Head and Neck HNSAVPAC I and cyclophospahmide treatment of thymoma/thymic carcinoma with cyclophosphamide, cyclophosphamide (cont'd) tablet, injectable Lung LUOTCAV I doxorubicin and vincristine

cyclophosphamide (cont'd) tablet, injectable Lung treatment of thymoma with platinum, doxorubicin and cyclophosphamide LUOTPAC I

treatment of extensive small cell lung cancer with cyclophosphamide, cyclophosphamide (cont'd) tablet, injectable Lung LUSCCAV I doxorubicin and vincristine treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCHOP I and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCHOPR I prednisone and rituximab treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with cyclophosphamide (cont'd) tablet, injectable Lymphoma doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab LYCHPBV I vedotin treatment of relapsed chronic lymphocytic leukemia using cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCLLCVPR I cyclophosphamide, vincristine, prednisone and rituximab treatment of Burkitt’s Lymphoma and Leukemia with cyclophosphamide, cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab advanced using cyclophosphamide, vincristine and cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCVP I prednisone treatment of Hodgkin's disease with cyclophosphamide, vinblastine, cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCVPPABO I procarbazine and prednisone treatment of advanced indolent lymphoma using cyclophosphamide, cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCVPR I vincristine, prednisone and rituximab therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia cyclophosphamide (cont'd) tablet, injectable Lymphoma LYCYCLO I or multiple myeloma using cyclophosphamide

* denotes change Page 18 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of lymphoma with dose-adjusted etoposide, doxorubicin, cyclophosphamide (cont'd) tablet, injectable Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I methotrexate treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic cyclophosphamide (cont'd) tablet, injectable Lymphoma LYFCR I leukemia with fludarabine, cyclophosphamide and rituximab

cyclophosphamide (cont'd) tablet, injectable Lymphoma lymphoma palliative chemotherapy LYPALL I

treatment of multiple myeloma using bortezomib, dexamethasone with or cyclophosphamide (cont'd) tablet, injectable Myeloma MYBORPRE I without cyclophosphamide as induction pre-stem cell transplant treatment of relapsed multiple myeloma using bortezomib, cyclophosphamide (cont'd) tablet, injectable Myeloma MYBORREL I dexamethasone with or without cyclophosphamide therapy of multiple myeloma using carfilzomib and dexamethasone with cyclophosphamide (cont'd) tablet, injectable Myeloma UMYCARDEX R or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with cyclophosphamide (cont'd) tablet, injectable Myeloma daratumumab in combination with bortezomib and dexamethasone with UMYDARBD R or without cyclophosphamide treatment of multiple myeloma using melphalan, prednisone and weekly cyclophosphamide (cont'd) tablet, injectable Myeloma bortezomib with the option of substituting cyclophosphamide for MYMPBOR I melphalan single dose cyclophosphamide priming therapy for multiple myeloma cyclophosphamide (cont'd) tablet, injectable Myeloma MYHDC I prior to autologous stem cell transplant SAIME alternating with SAVAC or SAVACM with support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s cyclophosphamide (cont'd) tablet, injectable Sarcoma SAALT2W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s cyclophosphamide (cont'd) tablet, injectable Sarcoma SAALT3W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma summary for treatment of recurrent/refractory neuroblastoma, ewing’s cyclophosphamide (cont'd) tablet, injectable Sarcoma sarcoma, osteogenic sarcoma or rhabdomyosarcoma with SAAVTC I /cyclophosphamide treatment of with vincristine, doxorubicin and cyclophosphamide (cont'd) tablet, injectable Sarcoma SAVAC I cyclophosphamide Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced cyclophosphamide (cont'd) tablet, injectable Sarcoma SAVACM I Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, cyclophosphamide (cont'd) tablet, injectable Sarcoma SAVDC I Dactinomycin and Cyclophosphamide treatment of recurrent/refractory rhabdomysarcoma in pediatric patients cyclophosphamide (cont'd) tablet, injectable Pediatric with cyclophosphamide, vinorelbine and on the COG I ARST0921 protocol* Other tumour site Not Otherwise cyclophosphamide (cont'd) tablet, injectable code followed by I Specified ‘NOS’ (e.g. BRNOS)

* denotes change Page 19 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES cytopenias associated with lymphoproliferative disorder of large granular cyclosporine capsule Lymphoma LYCSPA I lymphocytes treatment of hemophagocytic lymphohistiocytosis with etoposide, cyclosporine capsule Lymphoma HLHETCSPA I dexamethasone and cyclosporine injectable Leukemia & BMT therapy of acute myeloid leukemia using low dose cytarabine LKAMLCYT I Treatment of Acute Myeloid Leukemia using cytarabine injectable Leukemia & BMT ULKGEMOZ R with Induction and Consolidation Chemotherapy treatment of Burkitt’s lymphoma and leukemia with cyclophosphamide, cytarabine injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab cytarabine injectable Lymphoma treatment of lymphoma using intrathecal methotrexate and cytarabine LYIT I treatment of Burkitt’s lymphoma and leukemia with ifosfamide, mesna, cytarabine (cont'd) injectable Lymphoma LYIVACR I etoposide, cytarabine and rituximab therapy for solid tumours using intrathecal methotrexate and/or cytarabine (cont'd) injectable Miscellaneous Origins MOIT I and/or cytarabine Other tumour site Not Otherwise cytarabine (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. LYNOS)

* denotes change Page 20 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant treatment of stage III and IV, BRAF-mutated, fully resected capsule Skin & Melanoma USMAJDT R melanoma using dabrafenib and treatment of BRAF V600 mutation-positive unresectable or metastatic dabrafenib capsule Skin & Melanoma SMAVDAB I melanoma using dabrafenib treatment of BRAF V600 mutation-positive unresectable or metastatic dabrafenib capsule Skin & Melanoma SMAVDT I melanoma using dabrafenib and trametinib treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine dacarbazine injectable Lymphoma LYABVD I and dacarbazine Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with dacarbazine (cont'd) injectable Lymphoma LYAVDBV I Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin adjuvant treatment of patients with soft tissue sarcoma using doxorubicin dacarbazine (cont'd) injectable Sarcoma SAAJADIC I and dacarbazine treatment of patients with soft tissue sarcoma using doxorubicin and dacarbazine injectable Sarcoma SAAVADIC I dacarbazine dacarbazine (cont'd) injectable Sarcoma high dose single agent dacarbazine for metastatic soft tissue sarcoma SADTIC I therapy for metastatic malignant melanoma using high dose single agent dacarbazine injectable Skin & Melanoma SMDTIC I dacarbazine Other tumour site Not Otherwise dacarbazine (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. SMNOS) therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using dactinomycin injectable Gynecology etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, GOTDEMACO I cyclophosphamide and vincristine GOTDMR Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using dactinomycin (cont'd) injectable Gynecology (previously I Dactinomycin and Methotrexate GOTDLR) Therapy for Low-Risk Gestational Trophoblastic Cancer using dactinomycin (cont'd) injectable Gynecology GOTDLRA I Dactinomycin Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, dactinomycin injectable Sarcoma SAVDC I Dactinomycin and Cyclophosphamide Other tumour site Not Otherwise dactinomycin injectable code followed by I Specified ‘NOS’ (e.g. SANOS) treatment of relapsed and refractory multiple myeloma with daratumumab injectable Myeloma daratumumab in combination with bortezomib and dexamethasone with UMYDARBD R or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with daratumumab injectable Myeloma UMYDARLD R daratumumab in combination with lenalidomide and dexamethasone Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using darolutamide tablet Genitourinary UGUNMPDAR R Darolutamide treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic tablet Leukemia & BMT LKCMLD I leukemia

* denotes change Page 21 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES first-line induction and consolidation therapy of acute promyelocytic daunorubicin injectable Leukemia & BMT LKATOP I leukemia using arsenic trioxide, tretinoin and daunorubicin Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin daunorubicin injectable Leukemia & BMT ULKGEMOZ R with Induction and Consolidation Chemotherapy Other tumour site Not Otherwise daunorubicin injectable code followed by I Specified ‘NOS’ (e.g. KSNOS) degarelix injectable Genitourinary therapy for prostate cancer using LHRH antagonist GUPLHRHA I neoadjuvant use in patients with non-metastatic operable giant cell denosumab (XGEVA®) injectable Sarcoma SANADENO I tumour of the bone Therapy for Metastatic Castration-Sensitive Prostate Cancer using dexamethasone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer dexamethasone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone

palliative therapy for metastatic hormone refractory prostate cancer GUPDOC I

treatment of hemophagocytic lymphohistiocytosis with etoposide, dexamethasone tablet Lymphoma HLHETCSPA I dexamethasone and cycloSPORINE treatment of refractory or relapsing extranodal natural killer or T-Cell dexamethasone tablet Lymphoma LYASPMEDEX I lymphoma using pegaspargase, methotrexate and dexamethasone dexamethasone (cont'd) tablet Lymphoma treatment of lymphoma with gemcitabine, dexamethasone and platinum LYGDP I treatment of lymphoma with gemcitabine, dexamethasone and platinum dexamethasone Lymphoma LYGDPR I tablet with rituximab dexamethasone (cont'd) tablet Lymphoma lymphoma palliative chemotherapy LYPALL I treatment of natural killer or T-Cell Lymphoma using dexamethasone, dexamethasone Lymphoma LYSMILE I tablet methotrexate, ifosfamide, pegaspargase and etoposide treatment of newly diagnosed nasal, extranodal natural killer (NK) or T- Not reimbursed for: dexamethasone (cont'd) tablet Lymphoma cell lymphoma, stage IE to IIE using concurrent radiation and weekly LYVIPDRT I anti-emetic treatment, steroid cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone replacement therapy, pre-taxane Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated use, or appetite stimulation dexamethasone (cont'd) tablet Myeloma UMYBLDF R Multiple Myeloma treatment of multiple myeloma using bortezomib, dexamethasone with or dexamethasone (cont'd) tablet Myeloma MYBORPRE I without cyclophosphamide as induction pre-stem cell transplant treatment of relapsed multiple myeloma using bortezomib, dexamethasone MYBORREL I tablet Myeloma dexamethasone with or without cyclophosphamide therapy of multiple myeloma using carfilzomib and dexamethasone with dexamethasone (cont'd) UMYCARDEX R tablet Myeloma or without cyclophosphamide therapy of multiple myeloma using carfilzomib, lenalidomide with dexamethasone (cont'd) tablet Myeloma UMYCARLD R dexamethasone treatment of relapsed and refractory multiple myeloma with dexamethasone daratumumab in combination with bortezomib and dexamethasone with UMYDARBD R tablet Myeloma or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with dexamethasone (cont'd) UMYDARLD R tablet Myeloma daratumumab in combination with lenalidomide and dexamethasone treatment of previously untreated multiple myeloma and not eligible for dexamethasone UMYLDF R tablet Myeloma stem cell transplant using lenalidomide with low-dose dexamethasone

* denotes change Page 22 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES therapy of relapsed multiple myeloma using lenalidomide with dexamethasone (cont'd) tablet Myeloma UMYLDREL R dexamethasone treatment of multiple myeloma using melphalan, prednisone and weekly dexamethasone (cont'd) bortezomib with the option of substituting cyclophosphamide for MYMPBOR I tablet Myeloma melphalan dexamethasone tablet Myeloma therapy of multiple myeloma using pomalidomide with dexamethasone UMYPOMDEX R patients with primary or metastatic disease exhibiting cerebral edema or Not reimbursed for: dexamethasone (cont'd) tablet Miscellaneous Origins CNS swelling; management of malignant brain tumours; management of MODEXA I anti-emetic treatment, steroid CNS lymphoma replacement therapy, pre-taxane Other tumour site use, or appetite stimulation Not Otherwise code followed by dexamethasone (cont'd) tablet I Specified ‘NOS’ (for e.g. CNNOS) Other tumour site Not Otherwise dexamethasone (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. BRNOS) pediatric patients with acute myeloid leukemia receiving anthracycline on injectable Pediatric I the COG AAML1031 protocol pediatric patients with neuroblastoma treated on the CCG AEWS1031 dexrazoxane injectable Pediatric I protocol pediatric patients with rhabdomyosarcoma treated on the COG dexrazoxane (cont'd) injectable Pediatric I ARST08P1 protocol treatment of pediatric patients with high-risk neuroblastoma who achieve dinutuximab injectable Pediatric a response to prior first-line multi-agent, multimodal therapy using R dinutuximab in combination with sargramostim, aldesleukin and tretinoin neoadjuvant or adjuvant therapy for breast cancer using docetaxel injectable Breast BRAJDAC I cyclophosphamide, doxorubicin and docetaxel neoadjuvant or adjuvant therapy for breast cancer using docetaxel and docetaxel (cont'd) injectable Breast BRAJDC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using carboplatin, docetaxel (cont'd) injectable Breast BRAJDCARBT I docetaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, docetaxel (cont'd) injectable Breast BRAJFECD I epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, docetaxel (cont'd) injectable Breast BRAJFECDT I epirubicin and cyclophosphamide followed by docetaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, docetaxel (cont'd) injectable Breast BRAJTDC I docetaxel and cyclophosphamide combination with doxorubicin and cyclophosphamide as treatment of docetaxel (cont'd) injectable Breast BRLAACD I locally advanced breast cancer

* denotes change Page 23 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of locally advanced breast cancer using doxorubicin and docetaxel (cont'd) injectable Breast BRLAACDT I cyclophosphamide followed by docetaxel and trastuzumab first, second, or third line treatment of metastatic breast cancer patients docetaxel (cont'd) injectable Breast with ECOG performance status 0, 1, or 2, and greater than 3 month life BRAVDOC I expectancy weekly docetaxel regimen for metastatic breast cancer patients with poor docetaxel (cont'd) injectable Breast tolerance to 3-weekly docetaxel regimen (BRAVDOC) or high doses of BRAVDOC7 I dexamethasone used in BRAVDOC palliative therapy for metastatic breast cancer using gemcitabine and docetaxel (cont'd) injectable Breast BRAVGEMD I docetaxel palliative therapy for metastatic breast cancer using , docetaxel (cont'd) injectable Breast trastuzumab (Herceptin®) and docetaxel as first-line treatment for BRAVPTRAD I advanced breast cancer palliative treatment of metastatic esophagogastric adenocarcinoma with docetaxel (cont'd) injectable Gastrointestinal GIAVDOC I docetaxel perioperative treatment of resectable adenocarcinoma of the stomach, docetaxel (cont'd) injectable Gastrointestinal gastroesophageal junction or lower 1/3 esophagus using docetaxel, GIGFLODOC I oxaliplatin, infusional fluorouracil, and leucovorin combination with carboplatin as primary treatment of advanced/recurrent docetaxel (cont'd) injectable Gynecology GOCXCAD I non-small cell cancer of the cervix in ambulatory care settings treatment of primarily advanced or recurrent endometrial cancer using docetaxel (cont'd) injectable Gynecology GOENDCAD I carboplatin and docetaxel primary treatment with visible or no visible residual tumour (moderate, high, or extreme risk) or treatment at relapse of invasive epithelial docetaxel (cont'd) injectable Gynecology GOOVCAD I ovarian, fallopian tube, and primary peritoneal cancer, using carboplatin and docetaxel treatment of progressive, platinum-refractory epithelial ovarian docetaxel (cont'd) injectable Gynecology GOOVDOC I carcinoma, primary peritoneal combination with gemcitabine for advanced or recurrent uterine sarcoma docetaxel (cont'd) injectable Gynecology GOSADG I cancer Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using docetaxel (cont'd) injectable Genitourinary GUBGEMDOC I Gemcitabine and Docetaxel

docetaxel (cont'd) injectable Genitourinary intravesical use for bladder cancer if BCG and not available GUNOS I

docetaxel (cont'd) injectable Genitourinary palliative therapy for metastatic hormone refractory prostate cancer GUPDOC I first-line treatment of castration sensitive, metastatic prostate cancer docetaxel (cont'd) injectable Genitourinary using docetaxel and androgen deprivation therapy with LHRH agonist or GUPDOCADT I LHRH antagonist with or without antiandrogen, or surgical castration treatment of recurrent or metastatic squamous cell carcinoma of the docetaxel (cont'd) injectable Head and Neck HNAVDOC I head and neck with docetaxel treatment of recurrent or metastatic squamous cell carcinoma of the docetaxel (cont'd) injectable Head and Neck HNAVPD I head and neck with platinum and docetaxel

* denotes change Page 24 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of locally advanced squamous cell carcinoma of the head and docetaxel (cont'd) injectable Head and Neck HNLADCF I neck with docetaxel, cisplatin and infusional fluorouracil combination with cisplatin as first line treatment of advanced non-small docetaxel (cont'd) injectable Lung LUAVDC I lung cancer docetaxel (cont'd) injectable Lung second-line treatment of non-small cell lung cancer LUAVDOC I combination with gemcitabine as second or third line therapy for soft docetaxel (cont'd) injectable Sarcoma SAAVGEMD I tissue sarcomas adjuvant therapy for breast cancer using doxorubicin and doxorubicin injectable Breast BRAJAC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and doxorubicin injectable Breast BRAJACT I cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using dose dense doxorubicin (cont'd) injectable Breast BRAJACTG I therapy: doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and doxorubicin injectable Breast BRAJACTT I cyclophosphamide followed by paclitaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using dose dense doxorubicin (cont'd) injectable Breast therapy: doxorubicin and cyclophosphamide followed by paclitaxel and BRAJACTTG I trastuzumab neoadjuvant or adjuvant therapy for early breast cancer using doxorubicin injectable Breast BRAJACTW I doxorubicin and cyclophosphamide followed by weekly paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin (cont'd) injectable Breast BRAJDAC I cyclophosphamide, doxorubicin and docetaxel

doxorubicin injectable Breast palliative therapy for metastatic breast cancer using weekly doxorubicin BRAVA7 I

palliative therapy for metastatic breast cancer using doxorubicin and doxorubicin (cont'd) injectable Breast BRAVAC I cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and doxorubicin (cont'd) injectable Breast BRLAACD I cyclophosphamide followed by docetaxel treatment of locally advanced breast cancer using doxorubicin and doxorubicin (cont'd) injectable Breast BRLAACDT I cyclophosphamide followed by docetaxel and trastuzumab neoadjuvant therapy for triple-negative breast cancer using carboplatin doxorubicin (cont'd) injectable Breast BRLACTWAC I and weekly paclitaxel followed by doxorubicin and cyclophosphamide Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose- doxorubicin (cont'd) injectable Breast Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by BRLACTWACG I Doxorubicin and Cyclophosphamide neoadjuvant therapy for breast cancer using dose dense therapy: doxorubicin (cont'd) injectable Breast BRLATACG I paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and doxorubicin (cont'd) injectable Breast BRLATWAC I cyclophosphamide followed by weekly paclitaxel doxorubicin (cont'd) injectable Gastrointestinal palliative therapy for hepatoma using doxorubicin GIA I transarterial chemoembolization (TACE) of doxorubicin (cont'd) injectable Gastrointestinal GIDEBTACE I using drug-eluting bead (DEB) loaded with doxorubicin

* denotes change Page 25 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Note: only funded when hepatic trans-arterial chemoembolization for primary or liver prescribed by specialists at BC doxorubicin (cont'd) injectable Gastrointestinal GIEMBOL I metastasis Cancer VC & Royal Jubilee Hospital palliative therapy for pancreatic endocrine tumours using streptozocin doxorubicin (cont'd) injectable Gastrointestinal GIENDO2 I and doxorubicin hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with doxorubicin (cont'd) injectable Gastrointestinal GIPMHIPEC I peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel

doxorubicin (cont'd) injectable Genitourinary palliative therapy for advanced adrenal cortical cancer using doxorubicin GUAVD I

treatment of metastatic adrenalcortical cancer with doxorubicin, Not reimbursed for bladder doxorubicin (cont'd) injectable Genitourinary GUEDPM I etoposide, cisplatin and mitotane instillations therapy for transitional cell cancers of the urothelium using methotrexate, doxorubicin (cont'd) injectable Genitourinary GUMVAC I vinblastine, doxorubicin and cisplatin doxorubicin (cont'd) injectable Gynecology for use in patients with advanced endometrial cancer GOENDD I doxorubicin (cont'd) injectable Gynecology for use in patients with advanced uterine sarcoma GOSAD I doxorubicin (cont'd) injectable Head and Neck palliative therapy for advanced thyroid cancers using doxorubicin HNOTAVD I palliative therapy for advanced salivary gland cancers using doxorubicin (cont'd) injectable Head and Neck HNSAVFAC I cyclophosphamide, doxorubicin and fluorouracil treatment of advanced salivary gland cancers with platinum, doxorubicin doxorubicin (cont'd) injectable Head and Neck HNSAVPAC I and cyclophospahmide treatment of thymoma/thymic carcinoma with cyclophosphamide, doxorubicin (cont'd) injectable Lung LUOTCAV I doxorubicin and vincristine

doxorubicin (cont'd) injectable Lung treatment of thymoma with platinum, doxorubicin, and cyclophosphamide LUOTPAC I

treatment of extensive small cell lung cancer with cyclophosphamide, doxorubicin (cont'd) injectable Lung LUSCCAV I doxorubicin and vincristine treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine doxorubicin (cont'd) injectable Lymphoma LYABVD I and dacarbazine Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with doxorubicin (cont'd) injectable Lymphoma LYAVDBV I Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine doxorubicin (cont'd) injectable Lymphoma LYCHOP I and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, doxorubicin (cont'd) injectable Lymphoma LYCHOPR I prednisone and rituximab central nervous system prophylaxis with high dose methotrexate, CHOP doxorubicin (cont'd) injectable Lymphoma LYCHOPRMTX I and rituximab in diffuse large B-cell lymphoma treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with doxorubicin (cont'd) injectable Lymphoma doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab LYCHPBV I vedotin treatment of burkitt’s lymphoma and leukemia with cyclophosphamide, doxorubicin (cont'd) injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab

* denotes change Page 26 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, doxorubicin (cont'd) injectable Lymphoma LYCVPPABO I procarbazine and prednisone treatment of lymphoma with dose-adjusted etoposide, doxorubicin, doxorubicin (cont'd) injectable Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I methotrexate doxorubicin (cont'd) injectable Lymphoma lymphoma palliative chemotherapy LYPALL I therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide- doxorubicin (cont'd) injectable Sarcoma SAAI I mesna 3-day doxorubicin, ifosfamide and mesna for use in patients with doxorubicin (cont'd) injectable Sarcoma SAAI3 I advanced soft tissue sarcoma doxorubicin for adjuvant use for patients with non-metastatic operable doxorubicin (cont'd) injectable Sarcoma SAAJA I large high grade soft tissue sarcoma adjuvant treatment of patients with soft tissue sarcoma using doxorubicin doxorubicin (cont'd) injectable Sarcoma SAAJADIC I and dacarbazine doxorubicin (cont'd) injectable Sarcoma adjuvant therapy for osteosarcoma using doxorubicin and cisplatin SAAJAP I SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s doxorubicin (cont'd) injectable Sarcoma SAALT2W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s doxorubicin (cont'd) tablet, injectable Sarcoma SAALT3W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma doxorubicin (cont'd) injectable Sarcoma therapy for advanced soft tissue sarcoma using doxorubicin SAAVA I treatment of patients with soft tissue sarcoma using doxorubicin and doxorubicin (cont'd) injectable Sarcoma SAAVADIC I dacarbazine doxorubicin (cont'd) injectable Sarcoma therapy of advanced osteosarcoma using doxorubicin and cisplatin SAAVAP I treatment of sarcomas with vincristine, doxorubicin and doxorubicin (cont'd) injectable Sarcoma SAVAC I cyclophosphamide Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced doxorubicin (cont'd) injectable Sarcoma SAVACM I Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna Other tumour site Not Otherwise Not reimbursed for bladder doxorubicin (cont'd) injectable code followed by I Specified instillations ‘NOS’ (e.g. BRNOS)

* denotes change Page 27 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES doxorubicin pegylated treatment of platinum resistant epithelial ovarian cancer with injectable Gynecology GOOVBEVLD I liposomal bevacizumab and pegylated liposomal doxorubicin doxorubicin pegylated first line treatment of epithelial ovarian cancer using doxorubicin injectable Gynecology GOOVFPLDC I liposomal pegylated liposomal and carboplatin doxorubicin pegylated treatment of epithelial ovarian cancer relapsing after primary treatment injectable Gynecology GOOVLDOX I liposomal using pegylated liposomal doxorubicin doxorubicin pegylated treatment of epithelial ovarian cancer relapsing after primary treatment injectable Gynecology GOOVPLDC I liposomal using pegylated liposomal doxorubicin and carboplatin doxorubicin pegylated injectable Kaposi's Sarcoma Kaposi’s sarcoma KSLDO I liposomal drug-eluting bead (DEB) transarterial chemoembolization (TACE) of hepatocellular carcinoma loaded with doxorubicin (DC other Gastrointestinal GIDEBTACE I using drug-eluting bead (DEB) loaded with doxorubicin Bead® or HepaSphere™) treatment of locally advanced non-small cell lung cancer using injectable Lung LULADUR I durvalumab treatment of locally advanced non-small cell lung cancer using 4-weekly durvalumab injectable Lung LULADUR4 I durvalumab treatment of non-metastatic castration resistant prostate cancer using tablet Genitourinary UGUNMPENZ R enzalutamide treatment of metastatic castration resistant prostate cancer using enzalutamide tablet Genitourinary UGUPENZ R enzalutamide adjuvant therapy for breast cancer using fluorouracil, epirubicin and epirubicin injectable Breast BRAJFEC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin injectable Breast BRAJFECD I epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, epirubicin (cont'd) injectable Breast BRAJFECDT I epirubicin and cyclophosphamide followed by docetaxel and trastuzumab treatment of operable cancer of the stomach, stomach-esophagus epirubicin (cont'd) injectable Gastrointestinal junction or lower 1/3 esophagus, given before and after surgery, using GIGECC I epirubicin, cisplatin and capecitabine

epirubicin (cont'd) injectable Genitourinary intravesical use for bladder cancer if BCG and mitomycin C not available GUNOS I Other tumour site Not Otherwise epirubicin (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. BRNOS) injectable Breast Palliative Therapy for Metastatic Breast Cancer using Eribulin BRAVERIB I eribulin injectable Sarcoma Palliative Therapy for Metastatic Sarcoma using Eribulin SAAVERIB I tablet Lung second or third line treatment of advanced non-small cell lung cancer LUAVERL I maintenance therapy of advanced non-small cell lung cancer after first- erlotinib tablet Lung LUAVMTNE I line chemotherapy

* denotes change Page 28 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES capsule/ etoposide Neuro-Oncology carboplatin and etoposide in the treatment of recurrent ependymoma CNCARV I injectable capsule/ palliative treatment of patients with recurrent malignant gliomas and etoposide Neuro-Oncology CNETO I injectable ependymoma using low dose etoposide capsule/ therapy for recurrent malignant brain tumours using temozolomide and etoposide Neuro-Oncology CNTMZETO I injectable etoposide capsule/ palliative therapy of neuroendocrine tumours using cisplatin and etoposide Gastrointestinal GIPE I injectable etoposide capsule/ therapy of non-dysgerminomatous ovarian germ cell cancer using etoposide Gynecology GOBEP I injectable bleomycin, etoposide and cisplatin capsule/ therapy of dysgerminomatous ovarian germ cell cancer using cisplatin etoposide Gynecology GOEP I injectable and etoposide capsule/ treatment of relapsed/progressing epithelial ovarian, primary peritoneal, etoposide Gynecology GOOVETO I injectable or fallopian tube carcinoma using etoposide capsule/ etoposide (cont'd) Gynecology treatment of small-cell gynecologic cancer with cisplatin and etoposide GOSCPE I injectable capsule/ treatment of small-cell gynecologic cancer with cisplatin and etoposide etoposide Gynecology GOSCPERT I injectable with radiation therapy therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using capsule/ etoposide (cont'd) Gynecology etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, GOTDEMACO I injectable cyclophosphamide and vincristine capsule/ curative therapy for germ cell cancer using bleomycin, etoposide and etoposide (cont'd) Genitourinary GUBEP I injectable cisplatin capsule/ treatment of metastatic adrenalcortical cancer with doxorubicin, etoposide (cont'd) Genitourinary GUEDPM I injectable etoposide, cisplatin and mitotane capsule/ etoposide (cont'd) Genitourinary therapy for nonseminoma germ cell cancer using etoposide-cisplatin GUEP I injectable capsule/ etoposide (cont'd) Genitourinary therapy of genitourinary small cell tumours with a platin and etoposide GUSCPE I injectable capsule/ therapy of genitourinary small cell tumors with a platin and etoposide with etoposide (cont'd) Genitourinary GUSCPERT I injectable radiation capsule/ nonseminoma consolidation/salvage protocol using etoposide, cisplatin, etoposide Genitourinary GUVIP2 I injectable ifosfamide, mesna capsule/ treatment of recurrent and metastatic squamous cell cancer with etoposide (cont'd) Head and Neck HNAVPE I injectable platinum and etoposide capsule/ treatment of recurrent and/or metastatic nasopharyngeal cancer with etoposide (cont'd) Head and Neck HNNAVPE I injectable platinum and etoposide capsule/ treatment of locally advanced non-small cell lung cancer using cisplatin etoposide (cont'd) Lung LULAPERT I injectable and etoposide with radiation capsule/ treatment of locally advanced non-small cell lung cancer using alternative etoposide (cont'd) Lung LULAPE2RT I injectable dosing of cisplatin and etoposide with radiation therapy

* denotes change Page 29 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES capsule/ etoposide (cont'd) Lung treatment of thymoma with cisplatin and etoposide LUOTPE I injectable capsule/ treatment of thymoma using cisplatin and etoposide with radiation etoposide (cont'd) Lung LUOTPERT I injectable therapy capsule/ treatment of cancer of unknown primary involving the thorax with cisplatin etoposide (cont'd) Lung LUPUPE I injectable and etoposide capsule/ therapy of extensive stage small cell lung cancer with cisplatin and etoposide (cont'd) Lung LUSCPE I injectable etoposide capsule/ therapy of limited stage small cell lung cancer using cisplatin and etoposide (cont'd) Lung LUSCPERT I injectable etoposide with radiation capsule/ palliative therapy of extensive stage small cell lung cancer with oral etoposide (cont'd) Lung LUSCPOE I injectable etoposide capsule/ treatment of hemophagocytic lymphohistiocytosis with etoposide, etoposide (cont'd) Lymphoma HLHETCSPA I injectable dexamethasone and cycloSPORINE treatment of lymphoma with dose-adjusted etoposide, doxorubicin, capsule/ etoposide (cont'd) Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I injectable methotrexate capsule/ treatment of burkitt’s lymphoma and leukemia with ifosfamide, mesna, etoposide (cont'd) Lymphoma LYIVACR I injectable etoposide, cytarabine and rituximab capsule/ etoposide (cont'd) Lymphoma lymphoma palliative chemotherapy LYPALL I injectable treatment of relapsed or refractory advanced stage aggressive B-cell non- capsule/ etoposide (cont'd) Lymphoma Hodgkin’s lymphoma with ifosfamide, carboplatin, etoposide and LYRICE I injectable rituximab capsule/ treatment of natural killer or T-Cell Lymphoma using dexamethasone, etoposide (cont'd) Lymphoma LYSMILE I injectable methotrexate, ifosfamide, pegaspargase and etoposide treatment of newly diagnosed nasal, extranodal natural killer (NK) or T- capsule/ etoposide (cont'd) Lymphoma cell lymphoma, stage IE to IIE using concurrent radiation and weekly LYVIPDRT I injectable cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone SAIME alternating with SAVAC or SAVACM with filgrastim support at capsule/ TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s etoposide (cont'd) Sarcoma SAALT2W I injectable Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at capsule/ THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s etoposide (cont'd) SAALT3W I injectable Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma capsule/ 3-Day etoposide & ifosfamide-mesna for patients with advanced soft etoposide (cont'd) Sarcoma SAAVIME3 I injectable tissue or bony sarcomas

* denotes change Page 30 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES capsule/ etoposide (cont'd) Sarcoma etoposide, ifosfamide-mesna (SAIME) for use in sarcomas SAIME I injectable capsule/ treatment of recurrent or metastatic Merkel cell carcinoma with cisplatin etoposide (cont'd) Skin & Melanoma SMMCCPE I injectable and etoposide Other tumour site capsule/ Not Otherwise etoposide (cont'd) code followed by I injectable Specified ‘NOS’ (e.g. HNNOS)

tablet Breast therapy for advanced breast cancer using everolimus and exemestane BRAVEVEX I

treatment of advanced neuroendocrine tumours of gastrointestinal origin everolimus tablet Gastrointestinal UGINETEV R TM (non-functional) using everolimus Note: AFINITOR® DISPERZ everolimus tablet Gastrointestinal palliative treatment of advanced pancreatic neuroendocrine tumours GIPNEVER I formulation not funded everolimus tablet Genitourinary therapy for advanced renal cancer using everolimus GUEVER I treatment of advanced neuroendocrine tumours of lung origin (non- everolimus (cont'd) tablet Lung ULUNETEV R functional) using everolimus neoadjuvant or adjuvant therapy for breast cancer using exemestane in exemestane tablet Breast BRAJEXE I postmenopausal women neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in exemestane tablet Breast BRAJLHRHAI I premenopausal women with high-risk early stage breast cancer exemestane tablet Breast therapy for advanced breast cancer using everolimus and exemestane BRAVEVEX I first or second line hormonal treatment for advanced breast cancer in exemestane tablet Breast BRAVEXE I postmenopausal women therapy for advanced breast cancer using a LHRH agonist and an exemestane (cont'd) tablet Breast BRAVLHRHA I aromatase inhibitor hormonal treatment for advanced endometrial cancer in postmenopausal exemestane (cont'd) tablet Gynecology GOENDAI I women Note: NEUPOGEN® brand will for inpatient administration only - see BC PharmaCare Special Authority filgrastim (GRASTOFIL®) injectable FILGRASTIM only be reimbursed for pediatric Form for indications covered inpatient administration fludarabine injectable/ tablet Leukemia & BMT BMTNOS I treatment of chronic lymphocytic leukemia or prolymphocytic leukemia fludarabine injectable/ tablet Lymphoma LYCLLFLUDR I with fludarabine and rituximab treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic fludarabine injectable/ tablet Lymphoma LYFCR I leukemia with fludarabine, cyclophosphamide and rituximab fludarabine injectable/ tablet Lymphoma chronic lymphocytic leukemia or low grade lymphoma LYFLU I fludarabine injectable/ tablet Lymphoma treatment of relapsed indolent lymphoma with fludarabine and rituximab LYFLUDR I fludarabine injectable/ tablet Pediatric pediatric patients with AML treated on the CCG-2961 study I treatment of metastatic adrenalcortical cancer with doxorubicin, tablet Genitourinary GUEDPM I etoposide, cisplatin and mitotane fludrocortisone (cont'd) tablet Genitourinary deficiency associated with mitotane use GUMITO I

* denotes change Page 31 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant therapy for high-risk breast cancer using cyclophosphamide fluorouracil injectable Breast BRAJCMFPO I (oral), methotrexate and fluorouracil adjuvant therapy for breast cancer using fluorouracil, epirubicin and fluorouracil (cont'd) injectable Breast BRAJFEC I cyclophosphamide neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, fluorouracil injectable Breast BRAJFECD I epirubicin and cyclophosphamide and docetaxel neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, fluorouracil (cont'd) injectable Breast BRAJFECDT I epirubicin and cyclophosphamide followed by docetaxel and trastuzumab palliative therapy for advanced breast cancer using cyclophosphamide, fluorouracil (cont'd) injectable Breast BRAVCMF I methotrexate and fluorouracil adjuvant combination chemotherapy for stage III and stage IIB colon fluorouracil (cont'd) injectable Gastrointestinal GIAJFFOX I cancer using oxaliplatin, fluorouracil and folinic acid (leucovorin) adjuvant therapy of colon cancer using fluorouracil injection and infusion fluorouracil (cont'd) injectable Gastrointestinal GIAJFL I and leucovorin infusion palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal using fluorouracil injection and infusion and folinic acid (leucovorin) GIAVFL I infusion combined modality therapy for locally advanced using fluorouracil (cont'd) injectable Gastrointestinal GIEFFOXRT I oxaliplatin, fluorouracil, leucovorin, and radiation therapy Note: only funded when hepatic trans-arterial chemoembolization for primary liver cancer or liver prescribed by specialists at BC fluorouracil (cont'd) injectable Gastrointestinal GIEMBOL I metastasis Cancer VC & Royal Jubilee Hospital palliative therapy for pancreatic endocrine tumours using streptozocin fluorouracil (cont'd) injectable Gastrointestinal GIENDO2 I and doxorubicin palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal GIFFIRB I using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal UGIFFIRPAN R using irinotecan, fluorouracil, leucovorin, and palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal GIFFOXB I using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal UGIFFOXPAN R using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic fluorouracil (cont'd) injectable Gastrointestinal adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid GIFIRINOX I (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal GIFOLFIRI I using irinotecan, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer fluorouracil (cont'd) injectable Gastrointestinal GIFOLFOX I using oxaliplatin, fluorouracil and folinic acid (leucovorin)

* denotes change Page 32 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES combined modality curative therapy for carcinoma of the anal canal using fluorouracil (cont'd) injectable Gastrointestinal GIFUART I mitomycin, fluorouracil and radiation therapy palliative chemotherapy for upper gastrointestinal tract cancer (gastric, fluorouracil (cont'd) injectable Gastrointestinal esophageal, gall bladder carcinoma and cholangiocarcinoma) and GIFUC I metastatic anal cancer using infusional fluorouracil and cisplatin combined modality curative therapy for carcinoma of the anal canal using fluorouracil (cont'd) injectable Gastrointestinal GIFUPART I cisplatin, infusional fluorouracil and radiation therapy adjuvant chemotherapy in gastric cancer patients with D2 resection fluorouracil (cont'd) injectable Gastrointestinal (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, GIGAJFFOX I fluorouracil, and leucovorin palliative treatment of metastatic or inoperable, locally advanced gastric fluorouracil (cont'd) injectable Gastrointestinal or gastroesophageal junction adenocarcinoma using cisplatin, infusional GIGAVCFT I fluorouracil and trastuzumab palliative treatment of metastatic or locally advanced gastric, fluorouracil (cont'd) injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOX I oxaliplatin, fluorouracil and leucovorin palliative treatment of metastatic or locally advanced HER-2 positive fluorouracil (cont'd) injectable Gastrointestinal gastric, gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOXT I oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, fluorouracil (cont'd) injectable Gastrointestinal gastroesophageal junction or lower 1/3 esophagus using docetaxel, GIGFLODOC I oxaliplatin, infusional fluorouracil, and leucovorin palliative combination chemotherapy for metastatic gastric or esophageal fluorouracil (cont'd) injectable Gastrointestinal GIGFOLFIRI I adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin) hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with fluorouracil (cont'd) injectable Gastrointestinal peritoneal carcinomatosis from limited advanced colorectal and GIHIPEC I appendiceal carcinomas using oxaliplatin and fluorouracil adjuvant chemotherapy for resected pancreatic adenocarcinoma using fluorouracil (cont'd) injectable Gastrointestinal GIPAJFIROX I irinotecan, oxaliplatin, fluorouracil and leucovorin Second-Line Treatment for Metastatic Pancreatic Cancer using fluorouracil (cont'd) injectable Gastrointestinal GIPAVFFIRI I Irinotecan, Fluorouracil and Leucovorin Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer fluorouracil (cont'd) injectable Gastrointestinal GIPAVFFOX I using Oxaliplatin, Fluorouracil and Leucovorin Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal fluorouracil (cont'd) injectable Gastrointestinal GIRAJFFOX I Cancer using Oxaliplatin, Fluorouracil and Leucovorin combined modality adjuvant therapy for high risk rectal carcinoma using fluorouracil (cont'd) injectable Gastrointestinal GIRINFRT I capecitabine, infusional fluorouracil and radiation therapy combined modality therapy for squamous cell cancer of the genitourinary fluorouracil (cont'd) injectable Genitourinary GUFUPRT I system using fluorouracil and cisplatin with radiation

* denotes change Page 33 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES fluorouracil and leucovorin for recurrent head and neck cancer fluorouracil (cont'd) injectable Head and Neck HNAVFUFA I (squamous cell carcinoma) treatment of advanced squamous cell carcinoma of the head and neck fluorouracil (cont'd) injectable Head and Neck HNAVFUP I cancer using fluorouracil and platinum First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head fluorouracil (cont'd) injectable Head and Neck UHNAVPFPMB R and Neck using Platinum, Fluorouracil and Pembrolizumab combined chemotherapy (carboplatin and fluorouracil) and radiation fluorouracil (cont'd) injectable Head and Neck treatment for locally advanced squamous cell carcinoma of the head and HNLACAFRT I neck treatment of locally advanced squamous cell carcinoma of the head and fluorouracil (cont'd) injectable Head and Neck HNLADCF I neck with docetaxel, cisplatin and infusional fluorouracil fluorouracil and leucovorin for recurrent head and neck cancer fluorouracil (cont'd) injectable Head and Neck HNNAVFUFA I (nasopharyngeal) treatment for advanced nasopharyngeal cancer of the head and neck fluorouracil (cont'd) injectable Head and Neck HNNAVFUP I using platinum and fluorouracil palliative therapy for advanced salivary gland cancers using fluorouracil (cont'd) injectable Head and Neck HNSAVFAC I cyclophosphamide, doxorubicin and fluorouracil treatment of advanced head and neck cancer using cisplatin and fluorouracil (cont'd) injectable Head and Neck HNSAVFUP I fluorouracil Other tumour site Not Otherwise fluorouracil (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. HNNOS) fluorouracil eyedrops Ocular Topical Therapy for Ocular Malignancies using Fluorouracil Eye Drops OCFU* I fluorouracil topical cream Skin & Melanoma skin cancer SMNOS I Not reimbursed for vasomotor flutamide tablet Genitourinary nonsteroidal treatment of prostate cancer GUPNSAA I symptoms (hot flashes) Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant fulvestrant injectable Breast UBRAVPBFLV R with or without LHRH Agonist Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant fulvestrant injectable Breast UBRAVRBFLV R with or without LHRH Agonist first-line treatment of epidermal mutation-positive tablet Lung LUAVGEFF I advanced NSCLC gemcitabine injectable Breast palliative therapy for metastatic breast cancer using gemcitabine BRAVGEM I palliative therapy for metastatic breast cancer using gemcitabine and gemcitabine injectable Breast BRAVGEMD I docetaxel as palliative therapy for metastatic breast cancer using cisplatin and gemcitabine (cont'd) injectable Breast BRAVGEMP I gemcitabine gemcitabine injectable Breast treatment of metastatic breast cancer using gemcitabine and paclitaxel BRAVGEMT I first-line palliative chemotherapy for advanced gallbladder cancer and gemcitabine (cont'd) injectable Gastrointestinal GIAVPG I cholangiocarcinoma using gemcitabine and cisplatin adjuvant chemotherapy for resected pancreatic adenocarcinoma using gemcitabine (cont'd) injectable Gastrointestinal GIPAJGCAP I capecitabine and gemcitabine adjuvant chemotherapy for pancreatic adenocarcinoma using gemcitabine (cont'd) injectable Gastrointestinal GIPAJGEM I gemcitabine palliative chemotherapy for pancreatic adenocarcinoma, gallbladder gemcitabine injectable Gastrointestinal GIPGEM I cancer, and cholangiocarcinoma using gemcitabine first line treatment of locally advanced and metastatic pancreatic cancer gemcitabine (cont'd) injectable Gastrointestinal GIPGEMABR I with paclitaxel-nab (ABRAXANE®) and gemcitabine

* denotes change Page 34 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of platinum resistant epithelial ovarian cancer with gemcitabine (cont'd) injectable Gynecology GOOVBEVG I bevacizumab and gemcitabine carboplatin and gemcitabine for the treatment of recurrent platinum- gemcitabine injectable Gynecology GOOVCAG I sensitive ovarian cancer palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal gemcitabine injectable Gynecology GOOVGEM I cancer using gemcitabine combination with docetaxel for advanced or recurrent uterine sarcoma gemcitabine (cont'd) injectable Gynecology GOSADG I cancer

gemcitabine (cont'd) injectable Genitourinary adjuvant therapy for urothelial carcinoma using cisplatin and gemcitabine GUAJPG I

combination with cisplatin for advanced transitional cell carcinoma of the gemcitabine (cont'd) injectable Genitourinary GUAVPG I bladder intravesical therapy for non-muscle invasive bladder cancer using gemcitabine (cont'd) injectable Genitourinary GUBGEM I gemcitabine Intravesical Therapy for Non-Muscle Invasive Bladder Cancer using gemcitabine (cont'd) injectable Genitourinary GUBGEMDOC I Gemcitabine and Docetaxel combination with cisplatin as neoadjuvant therapy for urothelial gemcitabine (cont'd) injectable Genitourinary GUNAJPG I carcinoma

gemcitabine (cont'd) injectable Genitourinary palliative therapy for germ cell cancers using paclitaxel and gemcitabine GUTAXGEM I

treatment of loco-regionally recurrent and/or metastatic nasopharyngeal gemcitabine (cont'd) injectable Head and Neck HNNAVGEM I cancer with gemcitabine treatment of local-regionally recurrent and/or metastatic nasopharyngeal gemcitabine (cont'd) injectable Head and Neck HNNAVPG I cancer with platinum and gemcitabine as induction treatment of locally advanced nasopharyngeal cancer with gemcitabine (cont'd) injectable Head and Neck HNNLAPG I cisplatin and gemcitabine combination with cisplatin or carboplatin as treatment of advanced non- gemcitabine (cont'd) injectable Lung LUAVPG I small cell lung cancer first-line treatment of advanced squamous non-small cell lung cancer gemcitabine (cont'd) injectable Lung ULUAVPGPMB R with platinum, gemcitabine and pembrolizumab gemcitabine (cont'd) injectable Lung treatment of malignant mesothelioma with platinum and gemcitabine LUMMPG I gemcitabine (cont'd) injectable Lymphoma treatment of lymphoma with gemcitabine, dexamethasone and platinum LYGDP I treatment of lymphoma with gemcitabine, dexamethasone and platinum gemcitabine (cont'd) injectable Lymphoma LYGDPR I with rituximab gemcitabine (cont'd) injectable Lymphoma palliative chemotherapy of LYPALL I treatment of pediatric patients with relapsed Hodgkin lymphoma with a gemcitabine (cont'd) injectable Pediatric I combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV) combination with docetaxel as second or third line therapy for soft tissue gemcitabine (cont'd) injectable Sarcoma SAAVGEMD I sarcomas Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin gemtuzumab ozogamicin injectable Leukemia & BMT LKGEMOZ* I with Induction and Consolidation Chemotherapy Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using tablet Leukemia & BMT ULKAMLGIL* R Gilteritinib

* denotes change Page 35 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES long acting neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in Breast BRAJLHRHAI I injectable premenopausal women with high-risk early stage breast cancer long acting neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist goserelin Breast BRAJLHRHT I injectable and tamoxifen long acting therapy for advanced breast cancer using a LHRH agonist and an goserelin (cont'd) Breast BRAVLHRHA I injectable aromatase inhibitor long acting combination therapy with tamoxifen palliative therapy for metastatic goserelin (cont'd) Breast BRAVLHRHT I injectable breast cancer long acting therapy of advanced breast cancer using palbociclib and aromatase goserelin (cont'd) Breast UBRAVPALAI R Not reimbursed for endometriosis injectable inhibitor with or without LHRH agonist long acting Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant goserelin (cont'd) Breast UBRAVPBFLV R injectable with or without LHRH Agonist long acting Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant goserelin (cont'd) Breast UBRAVRBFLV R injectable with or without LHRH Agonist long acting therapy of advanced breast cancer using ribociclib and aromatase goserelin (cont'd) Breast UBRAVRIBAI R injectable inhibitor with or without LHRH agonist long acting goserelin (cont'd) Genitourinary therapy for prostate cancer using LHRH agonist GUPLHRH I injectable treatment of hemophagocytic lymphohistiocytosis with etoposide, tablet, injectable Lymphoma HLHETCSPA I dexamethasone and cycloSPORINE Other tumour site Not reimbursed for supportive care Not Otherwise hydrocortisone (cont'd) tablet, injectable code followed by I Specified ‘NOS’ (e.g. LYNOS) Myeloid , including but not limited to: Acute myeloid leukemia, Myelodysplastic syndromes (e.g. Refractory ), Myeloproliferative hydroxyurea capsule Leukemia & BMT LKNOS I disease (e.g. Chronic myeloid leukemia, Polycythemia, Essential ) Lymphoid neoplasms, including but not limited to: Lymphoproliferative hydroxyurea capsule Lymphoma LYNOS I disease, Myeloma ibritumomab 90Y Palliative therapy for lymphoma using radioimmunotherapy: rituximab- injectable Lymphoma 90 LYRITZ I (ZEVALIN®) priming for ibritumomab Y (ZEVALIN®) treatment of previously untreated chronic lymphocytic leukemia or small capsule Lymphoma ULYFIBRU R lymphocytic lymphoma using ibrutinib treatment of relapsed or refractory chronic lymphocytic leukemia or small ibrutinib capsule Lymphoma LYIBRU I lymphocytic lymphoma using ibrutinib ibrutinib (cont'd) capsule Lymphoma treatment of relapsed/refractory mantle-cell lymphoma using ibrutinib LYMIBRU I Tumour site code Not Otherwise injectable followed by ‘NOS’ I Specified (e.g. BRNOS) treatment of relapsed/refractory chronic lymphocytic leukemia or small tablet Lymphoma LYIDELAR I lymphocytic lymphoma using idelalisib and rituximab

* denotes change Page 36 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES advanced therapy for relapsed testicular germ cell cancer using ifosfamide injectable Genitourinary GUTIP I paclitaxel, ifosfamide and cisplatin consolidation/ salvage treatment for germ cell cancer using vinblastine, ifosfamide injectable Genitourinary GUVEIP I cisplatin, ifosfamide and mesna nonseminoma consolidation/salvage protocol using etoposide, cisplatin, ifosfamide (cont'd) injectable Genitourinary GUVIP2 I ifosfamide, mesna treatment of burkitt’s lymphoma and leukemia with ifosfamide, mesna, ifosfamide (cont'd) injectable Lymphoma LYIVACR I etoposide, cytarabine and rituximab treatment of relapsed or refractory advanced stage aggressive B-cell non- ifosfamide (cont'd) injectable Lymphoma Hodgkin’s lymphoma with ifosfamide, carboplatin, etoposide and LYRICE I rituximab treatment of natural killer or T-Cell Lymphoma using dexamethasone, ifosfamide (cont'd) injectable Lymphoma LYSMILE I methotrexate, ifosfamide, pegaspargase and etoposide treatment of newly diagnosed nasal, extranodal natural killer (NK) or T- ifosfamide (cont'd) injectable Lymphoma cell lymphoma, stage IE to IIE using concurrent radiation and weekly LYVIPDRT I cisplatin followed by etoposide, ifosfamide, cisplatin and dexamethasone treatment of pediatric patients with relapsed Hodgkin lymphoma with a ifosfamide injectable Pediatric I combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV) therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide- ifosfamide injectable Sarcoma SAAI I mesna 3-day doxorubicin, ifosfamide and mesna for use in patients with ifosfamide (cont'd) injectable Sarcoma SAAI3 I advanced soft tissue sarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s ifosfamide (cont'd) injectable Sarcoma SAALT2W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s ifosfamide (cont'd) injectable Sarcoma SAALT3W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma ifosfamide injectable Sarcoma therapy for advanced soft tissue sarcoma using ifosfamide SAAVI I ifosfamide injectable Sarcoma 3-day ifosfamide for use in patients with advanced soft tissue sarcoma SAAVI3 I 3-Day etoposide & ifosfamide-mesna for patients with advanced soft ifosfamide injectable Sarcoma SAAVIME3 I tissue or bony sarcomas ifosfamide injectable Sarcoma etoposide, ifosfamide-mesna (SAIME) for use in sarcomas SAIME I Other tumour site Not Otherwise ifosfamide (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. LYNOS)

* denotes change Page 37 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES therapy for chronic myeloid leukemia and Ph+ acute lymphoblastic capsule/tablet Leukemia & BMT LKCMLI I leukemia pediatric patients with Philadelphia chromosome positive acute imatinib capsule/tablet Pediatric I lymphoblastic leukemia adjuvant therapy of C-Kit positive high risk gastrointestinal stromal cell imatinib capsule/tablet Sarcoma SAAJGI I tumours advanced c- positive and c-kit negative gastrointestinal stromal cell imatinib (cont'd) capsule/tablet Sarcoma SAAVGI I tumours advanced c-kit positive gastrointestinal stromal cell tumors using 800 mg imatinib capsule/tablet Sarcoma SAAVGIDD I dosing of imatinib imatinib capsule/tablet Skin & Melanoma treatment of advanced c-kit melanoma using imatinib SMAVI I topical immunotherapy for in-transit melanoma metastases, cutaneous imiquimod topical cream Skin & Melanoma SMIMI I lymphoma, basal cell carcinoma using imiquimod treatment of relapsed or refractory pre-B-cell acute lymphoblastic injectable Leukemia & BMT ULKINOZ R leukemia with inotuzumab ozogamicin palliative therapy for BCG-refractory superficial high-grade transitional interferon alfa injectable Genitourinary GUBCGIFN I cell carcinoma bladder with BCG and interferon bladder cancer interferon alfa injectable Leukemia & BMT LKNOS I Not reimbursed for hepatitis, interferon alfa (cont'd) injectable Lymphoma LYNOS I Kaposi’s Sarcoma interferon alfa (cont'd) injectable Myeloma MYNOS I interferon alfa injectable Skin & Melanoma basal cell carcinoma SMNOS I interferon alfa eyedrops Ocular topical therapy for ocular malignancies OCIFN I treatment of metastatic or advanced renal cell carcinoma using injectable Genitourinary GUAVIPNI I ipilimumab and first-line treatment of unresectable or metastatic melanoma using injectable Skin & Melanoma SMAVFIPI I ipilimumab treatment of advanced and metastatic melanoma after prior systemic ipilimumab injectable Skin & Melanoma SMAVIPI I therapy treatment of unresectable or metastatic melanoma using ipilimumab and ipilimumab injectable Skin & Melanoma USMAVIPNI R nivolumab palliative third line treatment of metastatic colorectal cancer with wild- irinotecan injectable Gastrointestinal GIAVCETIR I type KRAS using cetuximab and irinotecan palliative combination chemotherapy for metastatic colorectal cancer irinotecan (cont'd) injectable Gastrointestinal GICAPIRI I using irinotecan and capecitabine in patients unsuitable for GIFOLFIRI palliative combination chemotherapy for metastatic colorectal cancer irinotecan injectable Gastrointestinal GICIRB I using irinotecan, bevacizumab and capecitabine palliative combination chemotherapy for metastatic colorectal cancer irinotecan injectable Gastrointestinal GIFFIRB I using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer irinotecan injectable Gastrointestinal UGIFFIRPAN R using irinotecan, fluorouracil, leucovorin, and panitumumab

* denotes change Page 38 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES palliative combination chemotherapy for advanced pancreatic irinotecan (cont'd) injectable Gastrointestinal adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid GIFIRINOX I (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer irinotecan (cont'd) injectable Gastrointestinal GIFOLFIRI I using irinotecan, fluorouracil and folinic acid (leucovorin) second line palliative combination chemotherapy for metastatic gastric or irinotecan (cont'd) injectable Gastrointestinal esophageal adenocarcinoma using irinotecan, fluorouracil and folinic acid GIGFOLFIRI I (leucovorin) irinotecan (cont'd) injectable Gastrointestinal palliative chemotherapy of metastatic colorectal cancer using irinotecan GIIR I

palliative therapy of metastatic colorectal cancer in patients who may not irinotecan injectable Gastrointestinal GIIRINALT I tolerate the 3-weekly irinotecan schedule of GIIR adjuvant chemotherapy for resected pancreatic adenocarcinoma using irinotecan injectable Gastrointestinal GIPAJFIROX I irinotecan, oxaliplatin, fluorouracil and leucovorin Second-Line Treatment for Metastatic Pancreatic Cancer using irinotecan injectable Gastrointestinal GIPAVFFIRI I Irinotecan, Fluorouracil and Leucovorin second line treatment of extensive stage small cell lung cancer (SCLC) irinotecan injectable Lung LUSCPI I with irinotecan with or without platinum pediatric patients treated on the COG protocol ARST0531 for irinotecan (cont'd) injectable Pediatric I intermediate-risk rhabdomyosarcoma pediatric patients with recurrent pediatric neuroblastoma treated on the irinotecan (cont'd) injectable Pediatric I COG protocol ANBL0421 pediatric patients with high risk renal tumors treated on the COG protocol irinotecan (cont'd) injectable Pediatric I AREN0321 pediatric patients with high risk rhabdomyosarcoma treated on the COG irinotecan (cont'd) injectable Pediatric I protocol ARSTO431 pediatric patients with rhabdomyosarcoma treated on the COG irinotecan (cont'd) injectable Pediatric I ARST08P1 protocol pediatric patients with recurrent/refractory medulloblastomas/CNS PNET irinotecan (cont'd) injectable Pediatric I of childhood treated on the COG ACNS0821 protocol (ACCUTANE) capsule Pediatric pediatric patients with high risk neuroblastoma I pediatric patients treated on the COG protocol ACNS0332 for above isotretinoin (ACCUTANE™) capsule Pediatric I average risk medulloblastoma/PNE treatment of growth hormone secreting pituitary adenoma using lanreotide injectable Neuro-Oncology CNLAN I lanreotide symptomatic management of functional carcinoid and neuroendocrine lanreotide (cont'd) injectable Gastrointestinal UGILAN R tumours of the GI Tract using lanreotide lapatinib tablet Breast therapy for metastatic breast cancer using capecitabine and lapatinib BRAVLCAP I

* denotes change Page 39 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES lenalidomide capsule Leukemia & BMT therapy of myelodysplastic syndrome using lenalidomide ULKMDSL R Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated lenalidomide capsule Myeloma UMYBLDF R Multiple Myeloma therapy of multiple myeloma using carfilzomib, lenalidomide with lenalidomide capsule Myeloma UMYCARLD R dexamethasone treatment of relapsed and refractory multiple myeloma with lenalidomide capsule Myeloma UMYDARLD R daratumumab in combination with lenalidomide and dexamethasone treatment of previously untreated multiple myeloma and not eligible for lenalidomide capsule Myeloma UMYLDF R stem cell transplant using lenalidomide with low-dose dexamethasone therapy of relapsed multiple myeloma using lenalidomide with lenalidomide (cont'd) capsule Myeloma UMYLDREL R dexamethasone lenalidomide capsule Myeloma maintenance therapy of multiple myeloma using lenalidomide UMYLENMTN R capsule Gastrointestinal first-line therapy of advanced hepatocellular carcinoma using lenvatinib UGILEN R therapy for locally recurrent or metastatic, RAI-refractory differentiated lenvatinib capsule Head and Neck HNOTLEN I thyroid cancer using lenvatinib neoadjuvant or adjuvant therapy for breast cancer using in letrozole tablet Breast BRAJLET I postmenopausal women neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in letrozole (cont'd) tablet Breast BRAJLHRHAI I premenopausal women with high-risk early stage breast cancer first or second line hormonal treatment for advanced breast cancer in letrozole tablet Breast BRAVLET I postmenopausal women therapy for advanced breast cancer using a LHRH agonist and an letrozole (cont'd) tablet Breast BRAVLHRHA I aromatase inhibitor therapy of advanced breast cancer using palbociclib and aromatase letrozole tablet Breast UBRAVPALAI R inhibitor with or without LHRH agonist therapy of advanced breast cancer using ribociclib and aromatase letrozole tablet Breast UBRAVRIBAI R inhibitor with or without LHRH agonist hormonal treatment for advanced endometrial cancer in postmenopausal letrozole (cont'd) tablet Gynecology GOENDAI I women with contraindications to tamoxifen or intolerant of tamoxifen hormonal treatment for advanced ovarian cancer in postmenopausal letrozole (cont'd) tablet Gynecology GOOVAI I women

* denotes change Page 40 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of meningeal disease using high-dose methotrexate with leucovorin tablet, injectable Breast BRAVHDMTX I leucovorin rescue adjuvant combination chemotherapy for Stage III and Stage IIB colon leucovorin calcium tablet, injectable Gastrointestinal GIAJFFOX I cancer using oxaliplatin, fluorouracil and folinic acid (Leucovorin) adjuvant therapy of colon cancer using fluorouracil injection and infusion leucovorin calcium tablet, injectable Gastrointestinal GIAJFL I and leucovorin infusion palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) tablet, injectable Gastrointestinal using fluorouracil injection and infusion and folinic acid (leucovorin) GIAVFL I infusion combined modality therapy for locally advanced esophageal cancer using leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIEFFOXRT I oxaliplatin, fluorouracil, leucovorin, and radiation therapy palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIFFIRB I using irinotecan, fluorouracil, folinic acid (leucovorin) and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) injectable Gastrointestinal UGIFFIRPAN R using irinotecan, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIFFOXB I using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) tablet, injectable Gastrointestinal UGIFFOXPAN R using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic leucovorin calcium (cont'd) tablet, injectable Gastrointestinal adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid GIFIRINOX I (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium tablet, injectable Gastrointestinal GIFOLFIRI I using irinotecan, fluorouracil and folinic acid (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIFOLFOX I using oxaliplatin, fluorouracil and folinic acid (leucovorin) adjuvant chemotherapy in gastric cancer patients with D2 resection leucovorin calcium (cont'd) tablet, injectable Gastrointestinal (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, GIGAJFFOX I fluorouracil, and leucovorin palliative treatment of metastatic or locally advanced gastric, leucovorin calcium (cont'd) tablet, injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOX I oxaliplatin, fluorouracil and leucovorin palliative treatment of metastatic or locally advanced HER-2 positive leucovorin calcium (cont'd) tablet, injectable Gastrointestinal gastric, gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOXT I oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, leucovorin calcium (cont'd) tablet, injectable Gastrointestinal gastroesophageal junction or lower 1/3 esophagus using docetaxel, GIGFLODOC I oxaliplatin, infusional fluorouracil, and leucovorin palliative combination chemotherapy for metastatic gastric or esophageal leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIGFOLFIRI I adenocarcinoma using irinotecan, fluorouracil and folinic acid (leucovorin)

* denotes change Page 41 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant chemotherapy for resected pancreatic adenocarcinoma using leucovorin calcium (cont'd) injectable Gastrointestinal GIPAJFIROX I irinotecan, oxaliplatin, fluorouracil and leucovorin Second-Line Treatment for Metastatic Pancreatic Cancer using leucovorin calcium (cont'd) injectable Gastrointestinal GIPAVFFIRI I Irinotecan, Fluorouracil and Leucovorin Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer leucovorin calcium (cont'd) injectable Gastrointestinal GIPAVFFOX I using Oxaliplatin, Fluorouracil and Leucovorin Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal leucovorin calcium (cont'd) tablet, injectable Gastrointestinal GIRAJFFOX I Cancer using Oxaliplatin, Fluorouracil and Leucovorin therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using leucovorin calcium (cont'd) tablet, injectable Gynecology etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, GOTDEMACO I cyclophosphamide and vincristine GOTDMR Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using leucovorin calcium (cont'd) tablet, injectable Gynecology (previously I Dactinomycin and Methotrexate GOTDLR) fluorouracil and leucovorin for recurrent head and neck cancer leucovorin calcium (cont'd) tablet, injectable Head and Neck HNAVFUFA I (squamous cell carcinoma) fluorouracil and leucovorin for recurrent head and neck cancer leucovorin calcium (cont'd) tablet, injectable Head and Neck HNNAVFUFA I (nasopharyngeal) treatment of refractory or relapsing extranodal natural killer or T-Cell leucovorin calcium (cont'd) tablet, injectable Lymphoma LYASPMEDEX I lymphoma using pegaspargase, methotrexate and dexamethasone central nervous system prophylaxis with high dose methotrexate, CHOP leucovorin calcium (cont'd) tablet, injectable Lymphoma LYCHOPRMTX I and rituximab in diffuse large B-cell lymphoma treatment of Burkitt’s lymphoma and leukemia with cyclophosphamide, leucovorin calcium (cont'd) tablet, injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab Treatment of Primary and Secondary CNS Lymphoma with High-Dose leucovorin calcium (cont'd) tablet, injectable Lymphoma LYHDMRTEM* I Methotrexate, Rituximab and Temozolomide treatment of natural killer or T-Cell lymphoma using dexamethasone, leucovorin calcium (cont'd) tablet, injectable Lymphoma LYSMILE I methotrexate, ifosfamide, pegaspargase and etoposide Other tumour site Not Otherwise leucovorin calcium (cont'd) tablet, injectable code followed by I Specified ‘NOS’ (e.g. LYNOS)

* denotes change Page 42 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES long acting neoadjuvant or adjuvant ovarian suppression and aromatase inhibitor in leuprolide Breast BRAJLHRHAI I injectable premenopausal women with high-risk early stage breast cancer injectable, long neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist leuprolide Breast BRAJLHRHT I acting injectable and tamoxifen injectable, long therapy for advanced breast cancer using a LHRH agonist and an leuprolide (cont'd) Breast BRAVLHRHA I acting injectable aromatase inhibitor injectable, long combination therapy with tamoxifen palliative therapy for metastatic Not reimbursed for endometriosis. leuprolide Breast BRAVLHRHT I acting injectable breast cancer Leuprolide acetate IM injectable, long therapy of advanced breast cancer using palbociclib and aromatase (LUPRON®) and SC (ELIGARD®) leuprolide (cont'd) Breast UBRAVPALAI R acting injectable inhibitor with or without LHRH agonist injectables are both reimbursable injectable, long Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant for prostate cancer indications leuprolide Breast UBRAVPBFLV R acting injectable with or without LHRH Agonist (GUPLHRH). injectable, long Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant leuprolide Breast UBRAVRBFLV R acting injectable with or without LHRH Agonist injectable, long therapy of advanced breast cancer using ribociclib and aromatase leuprolide Breast UBRAVRIBAI R acting injectable inhibitor with or without LHRH agonist injectable, long leuprolide Genitourinary therapy for prostate cancer using LHRH agonist GUPLHRH I acting injectable lomustine capsule Neuro-Oncology lomustine for treatment of recurrent malignant brain tumors CNCCNU I adjuvant lomustine, cisplatin and vincristine in adult high-risk lomustine capsule Neuro-Oncology CNCCV I medulloblastoma or other primitive neuroectodermal tumour modified PCV chemotherapy of brain tumours using procarbazine, lomustine (cont'd) capsule Neuro-Oncology CNMODPCV I lomustine and vincristine lomustine (cont'd) capsule Lymphoma lymphoma palliative chemotherapy LYPALL I Other tumour site Not Otherwise lomustine (cont'd) capsule code followed by I Specified ‘NOS’ (e.g. CNNOS) Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-Dotatate radio- 177Lu-Dotatate Gastrointestinal (LUTATHERA) for Treatment in Patients with Somatostatin Receptor UGIPRRT R pharmaceutical Positive Midgut Neuroendocrine Tumours Approval from Health Canada mechlorethamine topical gel Lymphoma topical mechlorethamine in cutaneous T-Cell lymphoma LYMECHLOR I Special Access Programme is () (SAP) required for each patient Not reimbursed for appetite medroxyprogesterone tablet Gynecology non-aromatase inhibitor hormonal treatment of endometrial cancer GOENDH I stimulation or replacement therapy. megestrol tablet Breast breast cancer BRAVMEG I Not reimbursed for appetite stimulation or symptom megestrol tablet Gynecology non-aromatase inhibitor hormonal treatment of endometrial cancer GOENDH I management

* denotes change Page 43 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES conditioning therapy for autologous stem cell transplant using high dose melphalan tablet, injectable Leukemia & BMT BMTMM0301 I melphalan in the treatment of multiple myeloma melphalan tablet, injectable Myeloma treatment of multiple myeloma using melphalan and prednisone MYMP I treatment of multiple myeloma using melphalan, prednisone and weekly melphalan tablet, injectable Myeloma bortezomib with the option of substituting cyclophosphamide for MYMPBOR I melphalan Other tumour site Not Otherwise melphalan tablet, injectable code followed by I Specified ‘NOS’ (e.g. LKNOS) Tumour site code Not Otherwise 6- tablet followed by ‘NOS’ I Specified (e.g. LKNOS) therapy for relapsed testicular germ cell cancer using paclitaxel, mesna injectable Genitourinary GUTIP I ifosfamide and cisplatin (TIP) consolidation/ salvage treatment for germ cell cancer using vinblastine, mesna Genitourinary GUVEIP I cisplatin, ifosfamide and mesna nonseminoma consolidation/salvage protocol using etoposide, cisplatin, mesna injectable GUVIP2 I Genitourinary ifosfamide, mesna Treatment of Burkitt’s lymphoma and leukemia with ifosfamide, mesna, mesna (cont'd) injectable Lymphoma LYIVACR I etoposide, cytarabine and rituximab treatment of relapsed or refractory advanced stage aggressive B-Cell mesna (cont'd) injectable LYRICE I Non-Hodgkin’s Lymphoma with ifosfamide, carboplatin, etoposide and treatment of Natural Killer or T-Cell Lymphoma using dexamethasone, mesna (cont'd) injectable LYSMILE I methotrexate, ifosfamide, pegaspargase and etoposide treatment of newly diagnosed Nasal, Extranodal Natural Killer (NK) or T- mesna (cont'd) injectable cell lymphoma, using concurrent radiation and weekly cisplatin followed LYVIPDRT I Approved for use ONLY as an uro- by etoposide, ifosfamide, cisplatin and dexamethasone protector for ifosfamide or high treatment of pediatric patients with relapsed Hodgkin lymphoma with a dose cyclophosphamide mesna injectable Pediatric I combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV) therapy for advanced soft tissue sarcoma using doxorubicin, ifosfamide- mesna injectable Sarcoma SAAI I mesna 3-day doxorubicin, ifosfamide and mesna for use in patients with mesna (cont'd) injectable Sarcoma SAAI3 I advanced soft tissue sarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s mesna (cont'd) injectable Sarcoma SAALT2W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s mesna (cont'd) injectable Sarcoma SAALT3W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma

* denotes change Page 44 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES mesna (cont'd) injectable Sarcoma therapy for advanced soft tissue sarcoma using ifosfamide SAAVI I mesna injectable Sarcoma 3-day ifosfamide for use in patients with advanced soft tissue sarcoma SAAVI3 I 3-day etoposide & ifosfamide-mesna for patients with advanced soft mesna injectable SAAVIME3 I Sarcoma tissue or bony sarcomas Sarcoma mesna (cont'd) injectable etoposide, ifosfamide-mesna (SAIME) for use in sarcomas SAIME I Approved for use ONLY as an uro- Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced mesna (cont'd) injectable Sarcoma SAVACM I protector for ifosfamide or high Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna dose cyclophosphamide mesna dosage modification for hematuria secondary to mesna (cont'd) injectable Supportive Care SCMESNA I oxazaphosphorines Other tumour site Not Otherwise mesna (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. SANOS) adjuvant therapy for high-risk breast cancer using cyclophosphamide methotrexate tablet, injectable Breast BRAJCMFPO I (oral), methotrexate and fluorouracil palliative therapy for advanced breast cancer using cyclophosphamide, methotrexate (cont'd) tablet, injectable Breast BRAVCMF I methotrexate and fluorouracil treatment of meningeal disease using high-dose methotrexate with methotrexate (cont'd) tablet, injectable Breast BRAVHDMTX I leucovorin rescue therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using methotrexate tablet, injectable Gynecology etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, GOTDEMACO I cyclophosphamide and vincristine GOTDMR Therapy for Moderate Low-Risk Gestational Trophoblastic Cancer using methotrexate (cont'd) tablet, injectable Gynecology (previously I Dactinomycin and Methotrexate GOTDLR) therapy for transitional cell cancers of the urothelium using methotrexate, methotrexate tablet, injectable Genitourinary GUMVAC I vinblastine, doxorubicin and cisplatin Not reimbursed for rheumatoid treatment of head and neck cancer using methotrexate as standard arthritis, psoriasis. methotrexate tablet, injectable Head and Neck HNAVM I therapy methotrexate (cont'd) tablet, injectable Kaposi's Sarcoma therapy for Kaposi's Sarcoma using vinblastine-vincristine KSVB I treatment of hemophagocytic lymphohistiocytosis with etoposide, methotrexate (cont'd) tablet, injectable Lymphoma HLHETCSPA I dexamethasone and cycloSPORINE treatment of refractory or relapsing extranodal natural killer or T-Cell methotrexate (cont'd) tablet, injectable Lymphoma LYASPMEDEX I lymphoma using pegaspargase, methotrexate and dexamethasone central nervous system prophylaxis with high dose methotrexate, CHOP methotrexate (cont'd) tablet, injectable Lymphoma LYCHOPRMTX I and rituximab in diffuse large B-cell lymphoma treatment of burkitt’s lymphoma and leukemia with cyclophosphamide, methotrexate (cont'd) tablet, injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab treatment of lymphoma with dose-adjusted etoposide, doxorubicin, methotrexate (cont'd) tablet, injectable Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I methotrexate

* denotes change Page 45 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Treatment of Primary and Secondary CNS Lymphoma with High-Dose methotrexate (cont'd) tablet, injectable Lymphoma LYHDMRTEM* I Methotrexate, Rituximab and Temozolomide Central Nervous System Prophylaxis with High-Dose Methotrexate in methotrexate (cont'd) tablet, injectable Lymphoma LYHDMTXPRO I Diffuse Large B-Cell Lymphoma methotrexate (cont'd) tablet, injectable Lymphoma treatment of lymphoma using intrathecal methotrexate and cytarabine LYIT I treatment of Burkitt’s Lymphoma and Leukemia with ifosfamide, mesna, methotrexate (cont'd) tablet, injectable Lymphoma LYIVACR I etoposide, cytarabine and rituximab methotrexate (cont'd) tablet, injectable Lymphoma lymphoma palliative chemotherapy LYPALL I Not reimbursed for rheumatoid treatment of natural killer or T-Cell Lymphoma using dexamethasone, methotrexate (cont'd) tablet, injectable Lymphoma LYSMILE I arthritis, psoriasis. methotrexate, ifosfamide, pegaspargase and etoposide therapy for solid tumours using intrathecal methotrexate and/or thiotepa methotrexate (cont'd) tablet, injectable Miscellaneous Origins MOIT I and/or cytarabine palliative therapy for aggressive fibromatosis using weekly or alternate methotrexate (cont'd) tablet, injectable Sarcoma SAMV I week methotrexate and vinblastine intravenously Other tumour site Not Otherwise methotrexate (cont'd) tablet, injectable code followed by I Specified ‘NOS’ (e.g. MYNOS) treatment of cutaneous T-cell lymphoma (Sézary syndrome) with methoxsalen injectable Lymphoma ULYMFECP R extracorporeal photopheresis Only reimbursable when prescribed by physicians in the topical cream Skin & Melanoma topical therapy for skin cancer with PDT (Photodynamic Therapy) SMPDT I Skin Tumour Group within the (METVIX®) Skin PDT Program of the BC Cancer Agency therapy of FLT3+ acute myeloid leukemia using in midostaurin capsule Leukemia & BMT LKAMLMIDO I combination with induction and consolidation chemotherapy combined modality therapy for carcinoma of the anal canal using mitomycin injectable Gastrointestinal GICART I mitomycin, capecitabine and radiation therapy Only funded when prescribed by hepatic trans-arterial chemoembolization for primary liver cancer or liver mitomycin injectable Gastrointestinal GIEMBOL I specialists at BC Cancer VC & metastasis Royal Jubilee Hospital combined modality curative therapy for carcinoma of the anal canal using mitomycin (cont'd) injectable Gastrointestinal GIFUART I mitomycin, fluorouracil and radiation therapy chemotherapy of pseudomyxoma peritonei using intraperitoneal mitomycin (cont'd) injectable Gastrointestinal GIFUIP I mitomycin and fluorouracil

* denotes change Page 46 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with mitomycin (cont'd) injectable Gastrointestinal peritoneal carcinomatosis from limited advanced colorectal and GIHIPEC I appendiceal carcinomas using oxaliplatin and fluorouracil combined modality therapy for squamous cell cancer of the genitourinary mitomycin (cont'd) injectable Genitourinary GUFUPRT I system using fluorouracil and cisplatin with radiation intravesical therapy for non-muscle invasive cell bladder cancer using GUBMITO mitomycin injectable Genitourinary I mitomycin mitomycin eye drops Ocular eye drops as topical therapy for ocular malignancies OCMITO I Other tumour site Not Otherwise mitomycin (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. GUNOS) mitotane tablet Genitourinary treatment of advanced adrenal cortical cancer GUMITO I treatment of metastatic adrenalcortical cancer with doxorubicin, mitotane tablet Genitourinary GUEDPM I etoposide, cisplatin and mitotane palliative therapy for hormone-refractory prostate cancer using injectable Genitourinary GUPMX I mitoxantrone and prednisone Other tumour site Not Otherwise mitoxantrone injectable code followed by I Specified ‘NOS’ (e.g. BRNOS) tablet Leukemia & BMT treatment of chronic myeloid leukemia using nilotinib ULKCMLN R prostate carcinoma patients who are intolerant to bicalutamide or Not reimbursed for vasomotor nilutamide tablet Genitourinary GUPNSAA I flutamide, at 150 mg po daily symptoms (hot flashes) treatment of metastatic or advanced renal cell carcinoma using nivolumab injectable Genitourinary GUAVIPNI I ipilimumab and nivolumab treatment of metastatic or advanced renal cell carcinoma using GUAVNIV I nivolumab treatment of metastatic or advanced renal cell carcinoma using 4-weekly nivolumab (cont'd) injectable Genitourinary GUAVNIV4 I nivolumab palliative therapy for unresectable, platinum-refractory, recurrent or nivolumab injectable Head and Neck UHNAVNIV R metastatic squamous cell cancer of the head and neck using nivolumab palliative therapy for unresectable, platinum-refractory, recurrent or nivolumab injectable Head and Neck metastatic squamous cell cancer of the head and neck using 4-weekly UHNAVNIV4 R nivolumab nivolumab injectable Lung treatment of advanced non-small cell lung cancer using nivolumab LUAVNIV I treatment of advanced non-small cell lung cancer using 4-weekly nivolumab injectable Lung LUAVNIV4 I nivolumab Lymphoma treatment of relapsed or refractory Hodgkin lymphoma using nivolumab LYNIV I treatment of relapsed or refractory Hodgkin lymphoma using 4-weekly Lymphoma LYNIV4 I nivolumab adjuvant treatment of resected stage III-IV NED melanoma using nivolumab injectable Skin & Melanoma USMAJNIV R nivolumab

* denotes change Page 47 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant treatment of resected stage III-IV NED melanoma using 4- nivolumab (cont'd) injectable Skin & Melanoma USMAJNIV4 R weekly nivolumab treatment of unresectable or metastatic melanoma using ipilimumab and nivolumab injectable Skin & Melanoma USMAVIPNI R nivolumab nivolumab injectable Skin & Melanoma treatment of unresectable or metastatic melanoma using nivolumab SMAVNIV I treatment of unresectable or metastatic melanoma using 4-weekly nivolumab injectable Skin & Melanoma SMAVNIV4 I nivolumab treatment of previously untreated chronic lymphocytic leukemia using obinutuzumab injectable Lymphoma LYOBCHLOR I obinutuzumab in combination with chlorambucil treatment of rituximab-refractory follicular lymphoma with obinutuzumab obinutuzumab injectable Lymphoma LYOBBEND I in combination with bendamustine octreotide injectable Neuro-Oncology treatment of growth hormone secreting pituitary adenoma CNOCTLAR I management of non-functional neuroendocrine tumours of the GI tract octreotide injectable Gastrointestinal GINOS I using octreotide long acting octreotide Neuro-Oncology treatment of growth hormone secreting pituitary adenoma CNOCTLAR I injectable long acting management of non-functional neuroendocrine tumours of the GI tract octreotide Gastrointestinal UGINFOCLAR R injectable using octreotide (SANDOSTATIN LAR®) long acting neuroendocrine tumours of the mid-gut or (including carcinoid octreotide Gastrointestinal UGIOCTLAR R injectable tumours and VIPoma) with symptoms due to ectopic hormone secretion maintenance therapy of newly diagnosed, BRCA-mutated, platinum- tablet Gynecology UGOOVFOLAM R responsive epithelial ovarian cancer using olaparib Note: capsule formulation not maintenance treatment of relapsed, BRCA-mutated, platinum sensitive funded olaparib tablet Gynecology UGOOVOLAPM R and responsive epithelial ovarian cancer using olaparib treatment of EGFR mutation-positive advanced non-small cell tablet Lung ULUAVOSI R lung cancer with osimertinib first-line treatment of EGFR mutation-positive advanced non-small cell osimertinib tablet Lung ULUAVOSIF R lung cancer with osimertinib adjuvant combination chemotherapy for stage III and IIB colon cancer oxaliplatin injectable Gastrointestinal GIAJCAPOX I with capecitabine adjuvant combination chemotherapy for stage III and IIB colon cancer oxaliplatin (cont'd) injectable Gastrointestinal GIAJFFOX I with fluorouracil and folinic acid adjuvant combination chemotherapy for node-positive colon cancer using oxaliplatin injectable Gastrointestinal oxaliplatin and in patients intolerant to fluorouracil or GIAJRALOX I capecitabine palliative combination chemotherapy for metastatic colorectal cancer oxaliplatin injectable Gastrointestinal GICAPOX I using oxaliplatin and capecitabine palliative combination chemotherapy for metastatic colorectal cancer oxaliplatin (cont'd) injectable Gastrointestinal GICOXB I using oxaliplatin, bevacizumab and capecitabine

* denotes change Page 48 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES combined modality therapy for locally advanced esophageal cancer using oxaliplatin (cont'd) injectable Gastrointestinal GIEFFOXRT I oxaliplatin, fluorouracil, leucovorin, and radiation therapy palliative combination chemotherapy for metastatic colorectal cancer oxaliplatin injectable Gastrointestinal GIFFOXB I using oxaliplatin, fluorouracil, leucovorin, and bevacizumab palliative combination chemotherapy for metastatic colorectal cancer oxaliplatin injectable Gastrointestinal UGIFFOXPAN R using oxaliplatin, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for advanced pancreatic oxaliplatin (cont'd) injectable Gastrointestinal adenocarcinoma using irinotecan, oxaliplatin, fluorouracil and folinic acid GIFIRINOX I (leucovorin) palliative combination chemotherapy for metastatic colorectal cancer with oxaliplatin (cont'd) injectable Gastrointestinal GIFOLFOX I fluorouracil and folinic acid adjuvant chemotherapy in gastric cancer patients with D2 resection oxaliplatin (cont'd) injectable Gastrointestinal (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin GIGAJCOX I and capecitabine adjuvant chemotherapy in gastric cancer patients with D2 resection oxaliplatin injectable Gastrointestinal (node negative) or ineligible for adjuvant chemoradiation using oxaliplatin, GIGAJFFOX I fluorouracil, and leucovorin palliative treatment of metastatic or locally advanced gastric, oxaliplatin injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVCOX I capecitabine and oxaliplatin palliative treatment of metastatic or locally advanced gastric, oxaliplatin injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVCOXT I capecitabine, oxaliplatin and trastuzumab palliative treatment of metastatic or locally advanced gastric, oxaliplatin (cont'd) injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOX I oxaliplatin, fluorouracil and leucovorin palliative treatment of metastatic or locally advanced HER-2 positive oxaliplatin injectable Gastrointestinal gastric, gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOXT I oxaliplatin, fluorouracil, leucovorin, and trastuzumab perioperative treatment of resectable adenocarcinoma of the stomach, oxaliplatin injectable Gastrointestinal gastroesophageal junction or lower 1/3 esophagus using docetaxel, GIGFLODOC I oxaliplatin, infusional fluorouracil, and leucovorin hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with oxaliplatin (cont'd) injectable Gastrointestinal peritoneal carcinomatosis from limited advanced colorectal and GIHIPEC I appendiceal carcinomas using oxaliplatin and fluorouracil adjuvant chemotherapy for resected pancreatic adenocarcinoma using oxaliplatin (cont'd) injectable Gastrointestinal GIPAJFIROX I irinotecan, oxaliplatin, fluorouracil and leucovorin Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer oxaliplatin (cont'd) injectable Gastrointestinal GIPAVFFOX I using Oxaliplatin, Fluorouracil and Leucovorin Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal oxaliplatin injectable Gastrointestinal GIRAJCOX I Cancer using Oxaliplatin and Capecitabine Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal oxaliplatin (cont'd) injectable Gastrointestinal GIRAJFFOX I Cancer using Oxaliplatin, Fluorouracil and Leucovorin

* denotes change Page 49 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and paclitaxel injectable Breast BRAJACT I cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using dose dense paclitaxel injectable Breast BRAJACTG I therapy: doxorubicin and cyclophosphamide followed by paclitaxel neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and paclitaxel (cont'd) injectable Breast BRAJACTT I cyclophosphamide followed by paclitaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using dose dense paclitaxel (cont'd) injectable Breast therapy: doxorubicin and cyclophosphamide followed by paclitaxel and BRAJACTTG I trastuzumab neoadjuvant or adjuvant therapy for early breast cancer using paclitaxel (cont'd) injectable Breast BRAJACTW I doxorubicin and cyclophosphamide followed by weekly paclitaxel adjuvant therapy for breast cancer using weekly paclitaxel and paclitaxel injectable Breast BRAJTTW I trastuzumab paclitaxel injectable Breast treatment of metastatic breast cancer using gemcitabine and paclitaxel BRAVGEMT I palliative therapy for metastatic breast cancer using pertuzumab, paclitaxel (cont'd) injectable Breast trastuzumab (Herceptin®), and paclitaxel as first-line treatment for BRAVPTRAT I advanced breast cancer paclitaxel (cont'd) injectable Breast palliative therapy for metastatic breast cancer using paclitaxel BRAVTAX I palliative therapy for metastatic breast cancer using weekly paclitaxel paclitaxel injectable Breast BRAVTW I (given weekly for 3 weeks out of 4 weeks) (replaces BRAVT7) neoadjuvant therapy for triple-negative breast cancer using carboplatin paclitaxel (cont'd) injectable Breast BRLACTWAC I and weekly paclitaxel followed by doxorubicin and cyclophosphamide Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose- paclitaxel (cont'd) injectable Breast Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by BRLACTWACG I Doxorubicin and Cyclophosphamide neoadjuvant therapy for breast cancer using dose dense therapy: paclitaxel (cont'd) injectable Breast BRLATACG I paclitaxel followed by doxorubicin and cyclophosphamide treatment of locally advanced breast cancer using doxorubicin and paclitaxel injectable Breast BRLATWAC I cyclophosphamide followed by weekly paclitaxel First-Line Palliative Treatment of Metastatic Anal Squamous Cell paclitaxel (cont'd) injectable Gastrointestinal GIAAVCT I Carcinoma using Carboplatin and Weekly Paclitaxel neoadjuvant treatment of esophageal and gastroesophageal carcinomas paclitaxel (cont'd) injectable Gastrointestinal GIENACTRT I using carboplatin, paclitaxel and radiation therapy second-line therapy for metastatic or locally advanced gastric or paclitaxel (cont'd) injectable Gastrointestinal gastroesophageal junction cancer using weekly paclitaxel and GIGAVRAMT I hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with paclitaxel (cont'd) injectable Gastrointestinal GIPMHIPEC I peritoneal mesothelioma using doxorubicin, cisplatin and paclitaxel

* denotes change Page 50 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES alternative treatment of gynecological malignancies using cisplatin and paclitaxel (cont'd) injectable Gynecology GOCISP I paclitaxel Alternative Treatment of Gynecological Malignancies using paclitaxel (cont'd) injectable Gynecology GOCISPBEV I Bevacizumab, Cisplatin and Paclitaxel primary adjuvant treatment of adenocarcinoma/adenosquamous cancer paclitaxel (cont'd) injectable Gynecology of the cervix with carboplatin and paclitaxel preceding or following GOCXAJCAT I irradiation with or without cisplatin combination with carboplatin as primary treatment of advanced/recurrent paclitaxel (cont'd) injectable Gynecology GOCXCAT I non-small cell cancer of the cervix in ambulatory care settings

paclitaxel (cont'd) injectable Gynecology primarily advanced or recurrent endometrial cancer GOENDCAT I primary treatment of invasive epithelial ovarian, fallopian tube and paclitaxel (cont'd) injectable Gynecology primary peritoneal cancer with high risk of relapse using bevacizumab, GOOVCATB I carboplatin and paclitaxel primary treatment of invasive epithelial ovarian, fallopian tube and paclitaxel (cont'd) injectable Gynecology primary peritoneal cancer, with no visible residual tumour (moderate-high GOOVCATM I risk) ovarian cancer relapsing after complete remission of at least 4 months’ paclitaxel (cont'd) injectable Gynecology GOOVCATR I duration in response to primary treatment with carboplatin and paclitaxel primary treatment of visible residual (extreme risk) invasive epithelial paclitaxel (cont'd) injectable Gynecology GOOVCATX I ovarian cancer primary treatment of metastatic/recurrent cancer of the cervix with paclitaxel (cont'd) injectable Gynecology GOCXCATB I bevacizumab, carboplatin and paclitaxel treatment of platinum resistant epithelial ovarian cancer with paclitaxel (cont'd) injectable Gynecology UGOOVBEVP R bevacizumab and paclitaxel primary treatment of advanced epithelial ovarian, primary peritoneal, or paclitaxel (cont'd) injectable Gynecology GOOVDDCAT I fallopian tube carcinoma using carboplatin and weekly paclitaxel primary treatment of stage III less than or equal to 1 cm visible residual paclitaxel (cont'd) injectable Gynecology invasive epithelial ovarian cancer using intravenous and intraperitoneal GOOVIPPC I paclitaxel and intraperitoneal carboplatin progressive, platinum-refractory ovarian carcinoma, primary peritoneal paclitaxel (cont'd) injectable Gynecology GOOVTAX3 I carcinoma or fallopian tube carcinoma

paclitaxel (cont'd) injectable Genitourinary palliative therapy for germ cell cancers using paclitaxel and gemcitabine GUTAXGEM I

advanced therapy for relapsed testicular germ cell cancer using paclitaxel (cont'd) injectable Genitourinary GUTIP I paclitaxel, ifosfamide and cisplatin treatment for unresectable, locoregionally recurrent or metastatic paclitaxel (cont'd) injectable Head and Neck squamous cell carcinoma of the head and neck using paclitaxel and HNAVPC I cisplatin or carboplatin First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head paclitaxel (cont'd) injectable Head and Neck UHNAVPCPMB R and Neck with Paclitaxel, Carboplatin and Pembrolizumab treatment of recurrent or metastatic nasopharyngeal carcinoma with paclitaxel (cont'd) injectable Head and Neck HNNAVPC I carboplatin and paclitaxel

* denotes change Page 51 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant carboplatin and paclitaxel following resection of stage I, II and paclitaxel (cont'd) injectable Lung LUAJPC I IIIA non-small cell lung cancer combination with carboplatin as first line treatment of advanced non- paclitaxel (cont'd) injectable Lung LUAVPC I small cell lung cancer first-line treatment of advanced squamous non-small cell lung cancer paclitaxel (cont'd) injectable Lung ULUAVPCPMB R with paclitaxel, carboplatin and pembrolizumab treatment of locally advanced non-small cell lung cancer using paclitaxel (cont'd) injectable Lung LULACATRT I carboplatin and paclitaxel with radiation therapy primary treatment of cancer of unknown primary origin using carboplatin paclitaxel (cont'd) injectable Primary Unknown PUCAT I and paclitaxel treatment of recurrent or resistant pediatric malignant germ cell tumors paclitaxel (cont'd) injectable Pediatric I with paclitaxel, ifosfamide and carboplatin (COG protocol AGCT0521) Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 paclitaxel (cont'd) injectable Sarcoma SAAVTW I Weeks out of 4 Weeks Schedule) palliative therapy for metastatic breast cancer using paclitaxel-NAB paclitaxel-NAB (ABRAXANE) injectable Breast BRAVABR I (ABRAXANE) paclitaxel-nab first line treatment of locally advanced and metastatic pancreatic cancer injectable Gastrointestinal GIPGEMABR I (ABRAXANE®) (cont'd) with paclitaxel-NAB (ABRAXANE) and gemcitabine paclitaxel-nab alternative treatment of gynecological malignancies using carboplatin and injectable Gynecology GOCABR I (ABRAXANE®) (cont'd) paclitaxel NAB (ABRAXANE) paclitaxel-nab alternative treatment of gynecological malignancies using bevacizumab, injectable Gynecology GOCABRBEV I (ABRAXANE®) (cont'd) carboplatin and paclitaxel NAB (ABRAXANE) therapy of advanced breast cancer using palbociclib and aromatase palbociclib capsule Breast UBRAVPALAI R inhibitor with or without LHRH agonist Therapy of Advanced Breast Cancer using Palbociclib and Fulvestrant palbociclib capsule Breast UBRAVPBFLV R with or without LHRH Agonist adjuvant therapy for breast cancer in post-menopausal women using pamidronate injectable Breast BRAJPAM I pamidronate bony metastases associated with breast cancer for patients who do not pamidronate injectable Breast BRAVCLOD I tolerate oral clodronate Not reimbursed for hypercalcemia prevention of skeletal related events secondary to breast cancer using pamidronate injectable Breast BRAVPAM I pamidronate pamidronate injectable Myeloma multiple myeloma MYPAM I palliative third-line treatment of metastatic colorectal cancer using panitumumab injectable Gastrointestinal GIAVPANI I panitumumab with wild type KRAS palliative combination chemotherapy for metastatic colorectal cancer panitumumab injectable Gastrointestinal UGIFFIRPAN R using irinotecan, fluorouracil, leucovorin, and panitumumab palliative combination chemotherapy for metastatic colorectal cancer panitumumab injectable Gastrointestinal UGIFFOXPAN R using oxaliplatin, fluorouracil, leucovorin, and panitumumab tablet Genitourinary palliative therapy for renal cell carcinoma using pazopanib GUPAZO I

* denotes change Page 52 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES pegaspargase treatment of refractory or relapsing extranodal natural killer or T-Cell injectable Lymphoma LYASPMEDEX I (ONCASPAR®) lymphoma using pegaspargase, methotrexate and dexamethasone pegaspargase treatment of natural killer or T-Cell Lymphoma using dexamethasone, injectable Lymphoma LYSMILE I (ONCASPAR®) methotrexate, ifosfamide, pegaspargase and etoposide pegaspargase treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma injectable Lymphoma LKNOS, LYNOS I (ONCASPAR®) using pegaspargase (ONCOSPAR) pegaspargase injectable Pediatric pediatric patients with leukemia or lymphoma I (ONCASPAR®) (cont'd) peginterferon alfa-2a injectable Leukemia & BMT therapy of chronic myeloid neoplasms and hypereosinophilic syndrome LKPEGIFN I treatment of locally advanced or metastatic urothelial carcinoma using pembrolizumab injectable Genitourinary UGUAVPEM R pembrolizumab treatment of locally advanced or metastatic urothelial carcinoma using 6- pembrolizumab injectable Genitourinary UGUAVPEM6 R weekly pembrolizumab Treatment of Metastatic Renal Cell Carcinoma Using Pembrolizumab and pembrolizumab injectable Genitourinary GUAVPEMAX I Axitinib First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head pembrolizumab injectable Head and Neck UHNAVPCPMB R and Neck with Paclitaxel, Carboplatin and Pembrolizumab First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head pembrolizumab injectable Head and Neck UHNAVPFPMB R and Neck using Platinum, Fluorouracil and Pembrolizumab First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head pembrolizumab injectable Head and Neck UHNAVPMBF R and Neck with Pembrolizumab Maintenance Treatment of Advanced Squamous Cell Carcinoma of the pembrolizumab injectable Head and Neck HNAVPMBM I Head and Neck with Pembrolizumab first-line treatment of advanced squamous non-small cell lung cancer pembrolizumab injectable Lung ULUAVPCPMB R with paclitaxel, carboplatin and pembrolizumab first-line treatment of advanced squamous non-small cell lung cancer pembrolizumab injectable Lung ULUAVPGPMB R with platinum, gemcitabine and pembrolizumab second-line treatment of advanced non-small cell lung cancer using pembrolizumab injectable Lung LUAVPMB I pembrolizumab treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab injectable Lung LUAVPMB6 I pembrolizumab first-line treatment of advanced non-small cell lung cancer using pembrolizumab injectable Lung LUAVPMBF I pembrolizumab first-line treatment of advanced non-small cell lung cancer using 6-weekly pembrolizumab injectable Lung LUAVPMBF6 I pembrolizumab maintenance therapy of advanced non-small cell lung cancer with pembrolizumab injectable Lung LUAVPMBM I pembrolizumab maintenance therapy of advanced non-small cell lung cancer with 6- pembrolizumab injectable Lung LUAVPMBM6 I weekly pembrolizumab maintenance therapy of advanced non-squamous non-small cell lung pembrolizumab injectable Lung LUAVPPMBM I cancer with pemetrexed and pembrolizumab first-line treatment of advanced non-squamous non-small cell lung cancer pembrolizumab injectable Lung ULUAVPPPMB R with platinum, pemetrexed and pembrolizumab treatment of relapsed or refractory hodgkin lymphoma using pembrolizumab injectable Lymphoma LYPEM I pembrolizumab treatment of relapsed or refractory hodgkin lymphoma using 6-weekly pembrolizumab injectable Lymphoma LYPEM6 I pembrolizumab adjuvant treatment of resected stage III – IV NED melanoma using pembrolizumab injectable Skin & Melanoma USMAJPEM R pembrolizumab

* denotes change Page 53 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES adjuvant treatment of resected stage III – IV NED melanoma using 6- pembrolizumab injectable Skin & Melanoma USMAJPEM6 R weekly pembrolizumab

pembrolizumab (cont'd) injectable Skin & Melanoma treatment of unresectable or metastatic melanoma using pembrolizumab SMAVPEM I

treatment of unresectable or metastatic melanoma using 6-weekly pembrolizumab (cont'd) injectable Skin & Melanoma SMAVPEM6 I pembrolizumab pemetrexed injectable Lung second-line treatment of advanced non-small cell lung cancer LUAVPEM I maintenance therapy of advanced non-small cell lung cancer after first- pemetrexed injectable Lung LUAVPMTN I line chemotherapy first-line treatment of advanced non-small cell lung cancer with platinum pemetrexed injectable Lung LUAVPP I and pemetrexed maintenance therapy of advanced non-squamous non-small cell lung pemetrexed injectable Lung LUAVPPMBM I cancer with pemetrexed and pembrolizumab first-line treatment of advanced non-squamous non-small cell lung cancer pemetrexed injectable Lung ULUAVPPPMB R with platinum, pemetrexed and pembrolizumab pemetrexed (cont'd) injectable Lung treatment of malignant mesothelioma with platinum and pemetrexed LUMMPP I palliative therapy for metastatic breast cancer using pertuzumab, pertuzumab injectable Breast trastuzumab (Herceptin®) and docetaxel as first-line treatment for BRAVPTRAD I advanced breast cancer palliative therapy for metastatic breast cancer using pertuzumab, pertuzumab (cont'd) injectable Breast trastuzumab (Herceptin®), and paclitaxel as first-line treatment for BRAVPTRAT I advanced breast cancer plerixafor injectable hematopoietic stem cell mobilization PLERIXAFOR I pomalidomide capsule Myeloma therapy of multiple myeloma using pomalidomide with dexamethasone UMYPOMDEX R treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) injectable Lymphoma ULYPRA R with pralatrexate treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic tablet Leukemia & BMT ULKCMLP R leukemia using ponatinib suspension Pediatric pediatric patients I palliative therapy for metastatic castration resistant prostate cancer sing prednisone tablet Genitourinary GUPCABA I cabazitaxel and prednisone Therapy for Metastatic Castration-Sensitive Prostate Cancer using UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer prednisone (cont'd) tablet Genitourinary UGUPABI R Using Abiraterone and prednisone prednisone tablet Genitourinary palliative therapy for metastatic hormone refractory prostate cancer GUPDOC I palliative therapy for hormone-refractory prostate cancer using prednisone (cont'd) tablet Genitourinary GUPMX I mitoxantrone and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine prednisone tablet Lymphoma LYCHOP I and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, prednisone (cont'd) tablet Lymphoma LYCHOPR I prednisone and rituximab central nervous system prophylaxis with high dose methotrexate, CHOP prednisone tablet Lymphoma LYCHOPRMTX I and rituximab in diffuse large B-cell lymphoma

* denotes change Page 54 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of CD30-positive peripheral T-Cell Lymphoma (PTCL) with prednisone (cont'd) tablet Lymphoma doxorubicin, cyclophosphamide, prednisone (CHP) and brentuximab LYCHPBV I vedotin treatment of relapsed chronic lymphocytic leukemia using prednisone tablet Lymphoma LYCLLCVPR I cyclophosphamide, vincristine, prednisone and rituximab advanced indolent lymphoma using cyclophosphamide, vincristine and prednisone (cont'd) tablet Lymphoma LYCVP I prednisone treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, prednisone (cont'd) tablet Lymphoma LYCVPPABO I procarbazine and prednisone treatment of advanced indolent lymphoma using cyclophosphamide, prednisone tablet Lymphoma LYCVPR I vincristine, prednisone and rituximab therapy of lymphoma, Hodgkin's disease, chronic lymphocytic leukemia prednisone tablet Lymphoma LYCYCLO I or multiple myeloma using cyclophosphamide treatment of lymphoma with dose-adjusted etoposide, doxorubicin, prednisone (cont'd) tablet Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I methotrexate prednisone (cont'd) tablet Lymphoma lymphoma palliative chemotherapy LYPALL I Bortezomib, Lenalidomide and Dexamethasone for Previously Untreated prednisone (cont'd) tablet Myeloma UMYBLDF R Multiple Myeloma treatment of multiple myeloma using bortezomib, dexamethasone with or prednisone (cont'd) tablet Myeloma MYBORPRE I without cyclophosphamide as induction pre-stem cell transplant treatment of relapsed multiple myeloma using bortezomib, prednisone (cont'd) tablet Myeloma MYBORREL I dexamethasone with or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with prednisone (cont'd) tablet Myeloma daratumumab in combination with bortezomib and dexamethasone with UMYDARBD R or without cyclophosphamide treatment of relapsed and refractory multiple myeloma with prednisone (cont'd) tablet Myeloma UMYDARLD R daratumumab in combination with lenalidomide and dexamethasone prednisone (cont'd) tablet Myeloma treatment of multiple myeloma using melphalan and prednisone MYMP I treatment of multiple myeloma using melphalan, prednisone and weekly prednisone (cont'd) tablet Myeloma bortezomib with the option of substituting cyclophosphamide for MYMPBOR I melphalan Other tumour site Not Otherwise prednisone (cont'd) tablet code followed by I Specified ‘NOS’ (e.g. LKNOS)

* denotes change Page 55 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES modified PCV chemotherapy of brain tumours using procarbazine, procarbazine capsule Neuro-Oncology CNMODPCV I lomustine and vincristine

procarbazine capsule Neuro-Oncology standard procarbazine for second-line treatment of recurrent CNPROC I

treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, procarbazine (cont'd) capsule Lymphoma LYCVPPABO I procarbazine and prednisone procarbazine capsule Lymphoma lymphoma palliative chemotherapy LYPALL I Other tumour site Not Otherwise procarbazine (cont'd) capsule code followed by I Specified ‘NOS’ (e.g. CNNOS) quinagolide tablet Neuro-Oncology therapy for pituitary adenaomas using quinagolide CNQUIN I radio- therapy for metastatic castration resistant prostate cancer using radium- radium-223 Genitourinary GUPRAD I pharmaceutical 223 unresectable or metastatic colorectal adenocarcinoma for patients with raltitrexed injectable Gastrointestinal GIRALT I previous fluorouracil toxicity adjuvant combination chemotherapy for node-positive colon cancer using raltitrexed (cont'd) injectable Gastrointestinal oxaliplatin and raltitrexed in patients intolerant to fluorouracil or GIAJRALOX I capecitabine second-line therapy for metastatic or locally advanced gastric or ramucirumab injectable Gastrointestinal gastroesophageal junction cancer using weekly paclitaxel and GIGAVRAMT I ramucirumab third line treatment of advanced gastrointestinal stromal cell tumours tablet Sarcoma SAAVGR I (GIST's) using regorafenib regorafenib tablet Gastrointestinal treatment of advanced hepatocellular carcinoma using regorafenib GIREGO I Therapy of Advanced Breast Cancer using Ribociclib and Fulvestrant ribociclib tablet Breast UBRAVRBFLV R with or without LHRH Agonist therapy of advanced breast cancer using ribociclib and aromatase ribociclib tablet Breast UBRAVRIBAI R inhibitor with or without LHRH agonist

* denotes change Page 56 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES IV injectable pre-emptive rituximab therapy of Epstein-Barr virus related post- rituximab Leukemia & BMT BMTLPDRIT I only transplant lymphoproliferative disease IV / 1400 mg SC rituximab Lymphoma treatment of Non-Hodgkin Lymphoma with bendamustine and rituximab LYBENDR I injectable IV / 1400 mg SC rituximab Lymphoma treatment of indolent B-cell lymphoma with chlorambucil and rituximab LYCHLRR I injectable in combination with CHOP (cyclophosphamide, doxorubicin, prednisone, IV / 1400 mg SC rituximab (cont'd) Lymphoma vincristine), in all stages of newly diagnosed diffuse large B-cell LYCHOPR I injectable lymphoma and mantle cell lymphoma, advanced stage at diagnosis Note: Biosimilar rituximab IV / 1400 mg SC central nervous system prophylaxis with high dose methotrexate, CHOP (RIXIMYO®, RUXIENCE®) is rituximab Lymphoma LYCHOPRMTX I injectable and rituximab in diffuse large B-cell lymphoma funded for intravenous rituximab IV / 1600 mg SC treatment of relapsed/refractory chronic lymphocytic leukemia or small started on or after August 1st, rituximab Lymphoma LYCLLBENDR I injectable lymphocytic lymphoma with bendamustine and rituximab 2020. RITUXAN® is funded for IV / 1600 mg SC treatment of chronic lymphocytic leukemia with chlorambucil and intravenous rituximab started prior rituximab Lymphoma LYCLLCHLR I injectable rituximab to and continue beyond August IV / 1600 mg SC treatment of relapsed chronic lymphocytic leukemia using rituximab Lymphoma LYCLLCVPR I 1st, 2020. injectable cyclophosphamide, vincristine, prednisone and rituximab IV / 1600 mg SC treatment of previously untreated chronic lymphocytic leukemia (CLL) LYCLLFBR I injectable with bendamustine and rituximab IV / 1600 mg SC treatment of chronic lymphocytic leukemia or prolymphocytic leukemia rituximab (cont'd) Lymphoma LYCLLFLUDR I injectable with fludarabine and rituximab IV / 1400 mg SC treatment of Burkitt’s lymphoma and leukemia with cyclophosphamide, rituximab (cont'd) Lymphoma LYCODOXMR I injectable vincristine, doxorubicin, methotrexate, leucovorin and rituximab IV / 1400 mg SC combination with CVP for advanced stage indolent lymphoma at rituximab (cont'd) Lymphoma LYCVPR I injectable diagnosis

* denotes change Page 57 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of lymphoma with dose-adjusted etoposide, doxorubicin, IV / 1400 mg SC rituximab (cont'd) Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I injectable methotrexate IV / 1600 mg SC treatment of chronic lymphocytic leukemia (CLL) or prolymphocytic rituximab (cont'd) Lymphoma LYFCR I injectable leukemia with fludarabine, cyclophosphamide and rituximab IV / 1400 mg SC rituximab Lymphoma treatment of relapsed indolent lymphoma with fludarabine and rituximab LYFLUDR I injectable IV / 1400 mg SC treatment of lymphoma with gemcitabine, dexamethasone and platinum rituximab (cont'd) Lymphoma LYGDPR I injectable with rituximab IV / 1400 mg SC Treatment of Primary and Secondary CNS Lymphoma with High-Dose rituximab (cont'd) Lymphoma LYHDMRTEM* I injectable Methotrexate, Rituximab and Temozolomide IV / 1600 mg SC treatment of relapsed/refractory chronic lymphocytic leukemia or small rituximab (cont'd) Lymphoma LYIDELAR I Note: Biosimilar rituximab injectable lymphocytic lymphoma using idelalisib and rituximab IV / 1400 mg SC treatment of Burkitt’s lymphoma and leukemia with ifosfamide, mesna, (RIXIMYO®, RUXIENCE®) is rituximab (cont'd) Lymphoma LYIVACR I injectable etoposide, cytarabine and rituximab funded for intravenous rituximab treatment of relapsed or refractory advanced stage aggressive B-cell non- started on or after August 1st, IV / 1400 mg SC rituximab (cont'd) Lymphoma Hodgkin’s lymphoma with ifosfamide, carboplatin, etoposide and LYRICE I 2020. RITUXAN® is funded for injectable rituximab intravenous rituximab started prior follicular lymphoma progressive despite alkylating agents and to and continue beyond August IV / 1400 mg SC analogues (fludarabine or cladribine), post-transplant lymphoproliferative rituximab (cont'd) Lymphoma LYRITUX I 1st, 2020. injectable disease, or newly diagnosed (within 6 months) asymptomatic advanced follicular lymphoma IV injectable palliative therapy for lymphoma using radioimmunotherapy: rituximab- Lymphoma 90 LYRITZ I only priming for ibritumomab Y (ZEVALIN®) IV / 1400 mg SC rituximab (cont'd) Lymphoma maintenance treatment of indolent lymphoma LYRMTN I injectable IV / 1600 mg SC treatment of relapsed/refractory chronic lymphocytic leukemia or small rituximab (cont'd) Lymphoma LYVENETOR I injectable lymphocytic lymphoma using and rituximab pediatric patients treated on the COG protocols ANHL0221 for CD20 IV injectable positive post-transplant lymphoproliferative disease following solid organ Pediatric I only transplantation and ANHL01P1 for newly diagnosed advanced B-cell leukemia/lymphoma treatment of relapsed or refractory Peripheral T-Cell lymphoma (PTCL) injectable Lymphoma ULYROMI R with romidepsin tablet Leukemia & BMT treatment of symptomatic myelofibrosis with ruxolitinib ULKMFRUX R ruxolitinib tablet Leukemia & BMT treatment of with ruxolitinib ULKPCVRUX R

* denotes change Page 58 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES pediatric patients with neuroblastoma treated on the COG ANBL0032 sargramostim (SAP) injectable Pediatric I protocol pediatric patients with relapsed neuroblastoma treated on the COG Approval from Health Canada sargramostim injectable Pediatric I ANBL1021 protocol Special Access Programme is treatment of pediatric patients with high-risk neuroblastoma who achieve required for each patient sargramostim injectable Pediatric a response to prior first-line multi-agent, multimodal therapy using R dinutuximab in combination with sargramostim, aldesleukin and tretinoin treatment of Multicentric Castleman’s Disease (MCD) negative for siltuximab injectable Lymphoma Human Immunodeficiency Virus (HIV) and Human Herpes Virus-8 (HHV- LYSILTUX I 8) Using siltuximab sorafenib tablet Gastrointestinal sorafenib therapy for advanced hepatocellular carcinoma UGISORAF R

sorafenib tablet Genitourinary palliative therapy for renal cell carcinoma in patients after cytokine failure GUSORAF I

sorafenib tablet Leukemia & BMT therapy of acute myeloid leukemia using azacitidine and sorafenib LKAMLAS I palliative therapy for pancreatic endocrine tumours using streptozocin streptozocin injectable Gastrointestinal GIENDO2 I and doxorubicin Approval from Health Canada Other tumour site Special Access Programme is Not Otherwise streptozocin injectable code followed by I required for each patient Specified ‘NOS’ (e.g. GINOS) capsule Gastrointestinal as palliative treatment of advance pancreatic neuroendocrine tumours GIPNSUNI I palliative therapy for renal cell carcinoma in patients who are not suitable sunitinib capsule Genitourinary GUSUNI I candidates for interferon second line treatment of advanced c-kit positive gastrointestinal stromal sunitinib (cont'd) capsule Sarcoma SAAVGS I cell tumours (GIST's) after imatinib neoadjuvant or adjuvant therapy for breast cancer using a LHRH agonist tamoxifen tablet Breast BRAJLHRHT I and tamoxifen tamoxifen tablet Breast neoadjuvant or adjuvant therapy for breast cancer using tamoxifen BRAJTAM I

tamoxifen (cont'd) tablet Breast palliative therapy for breast cancer using a LHRH agonist and tamoxifen BRAVLHRHT I

tamoxifen tablet Breast palliative therapy for breast cancer BRAVTAM I endometrial cancernon-aromatase inhibitor hormonal treatment of tamoxifen tablet Gynecology GOENDH I endometrial cancer tamoxifen tablet Gynecology therapy for advanced ovarian cancer using tamoxifen GOOVTAM I tamoxifen (cont'd) tablet Head and Neck treatment of recurrent/metastatic salivary gland cancers HNSAVTAM I tamoxifen tablet Sarcoma recurrent desmoid tumors/aggressive fibromatosis SATAM I

* denotes change Page 59 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES concomitant (dual modality) and 12 cycles of adjuvant temozolomide for temozolomide capsule Neuro-Oncology CNAJ12TZRT I newly diagnosed astrocytomas and oligodendrogliomas with radiation concomitant and adjuvant temozolomide for newly diagnosed malignant temozolomide capsule Neuro-Oncology CNAJTZRT I gliomas with radiation treatment of elderly newly diagnosed glioma patient with concurrent and temozolomide capsule Neuro-Oncology CNELTZRT I adjuvant temozolomide and radiation therapy therapy for newly diagnosed malignant brain tumours with MGMT temozolomide capsule Neuro-Oncology CNTEM60 I methylation in elderly patients using temozolomide temozolomide capsule Neuro-Oncology therapy for malignant brain tumours CNTEMOZ I therapy for malignant brain tumours using metronomic dosing of temozolomide (cont'd) capsule Neuro-Oncology CNTEMOZMD I temozolomide therapy for recurrent malignant brain tumours using temozolomide and temozolomide (cont'd) capsule Neuro-Oncology CNTMZETO I etoposide palliative therapy of metastatic neuroendocrine cancer using temozolomide (cont'd) capsule Gastrointestinal GIAVTZCAP I temozolomide and capecitabine Treatment of Primary and Secondary CNS Lymphoma with High-Dose temozolomide (cont'd) capsule Lymphoma LYHDMRTEM* I Methotrexate, Rituximab and Temozolomide temozolomide (cont'd) capsule Pediatric pediatric patients with brain tumours I pediatric patients treated on the COG protocol ANBL0421 for recurrent temozolomide capsule Pediatric I neuroblastoma pediatric patients with rhabdomyosarcoma treated on the COG temozolomide (cont'd) capsule Pediatric I ARST08P1 protocol therapy for advanced solitary fibrous tumours and hemangiopericytoma temozolomide (cont'd) capsule Sarcoma SATEMBEV I using temozolomide and bevacizumab temozolomide (cont'd) capsule Skin & Melanoma palliative therapy for malignant melanoma with brain metastases SMAVTMZ I temsirolimus injectable Genitourinary therapy for advanced renal cancer using temsirolimus GUTEM I treatment of recurrent/refractory rhabdomysarcoma in pediatric patients temsirolimus injectable Pediatric with cyclophosphamide, vinorelbine and temsirolimus on the COG I ARST0921 protocol* Tumour site code Not Otherwise injectable followed by ‘NOS’ I Specified (e.g. GUNOS) Not reimbursed for symptom enanthate injectable Breast palliative therapy for metastatic breast cancer BRAVTEST I management or appetite stimulation Tumour site code Not Otherwise thioguanine tablet followed by ‘NOS’ I Specified (e.g. LYNOS)

* denotes change Page 60 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES therapy for solid tumours using intrathecal methotrexate and/or thiotepa thiotepa injectable Miscellaneous Origins MOIT I and/or cytarabine Other tumour site Not Otherwise thiotepa (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. GUNOS) thyrotropin alfa injectable Head and Neck radioiodine imaging in patients with thyroid cancer and treatment HNOTTSH I treatment of relapsed/progressive epithelial ovarian, fallopian tube or topotecan injectable Gynecology GOOVTOP I primary peritoneal cancer using topotecan topotecan (cont'd) injectable Lung second line treatment of recurrent small cell lung cancer LUSCTOP I topotecan (cont'd) injectable Pediatric pediatric sarcoma I intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) topotecan injectable Pediatric I pediatric neuroblastoma summary for treatment of recurrent/refractory neuroblastoma, ewing’s topotecan injectable Sarcoma sarcoma, osteogenic sarcoma or rhabdomyosarcoma with SAAVTC I topotecan/cyclophosphamide adjuvant treatment of stage III and IV, BRAF-mutated, fully resected trametinib tablet Skin & Melanoma USMAJDT R melanoma using dabrafenib and trametinib treatment of BRAF V600 mutation-positive unresectable or metastatic trametinib tablet Skin & Melanoma SMAVDT I melanoma using dabrafenib and trametinib treatment of BRAF V600 mutation-positive unresectable or metastatic trametinib tablet Skin & Melanoma SMAVTRA I melanoma using trametinib neoadjuvant or adjuvant therapy for breast cancer using doxorubicin and trastuzumab injectable Breast BRAJACTT I cyclophosphamide followed by paclitaxel and trastuzumab neoadjuvant or adjuvant therapy for breast cancer using dose dense trastuzumab therapy: doxorubicin and cyclophosphamide followed by paclitaxel and BRAJACTTG I Note: Biosimilar trastuzumab trastuzumab (HERZUMA®, TRAZIMERA®) is neoadjuvant or adjuvant therapy for breast cancer using carboplatin, trastuzumab (cont'd) Injectable Breast BRAJDCARBT I funded for treatment started on or docetaxel and trastuzumab after February 1st, 2020, except neoadjuvant or adjuvant therapy for breast cancer using fluorouracil, trastuzumab Injectable Breast BRAJFECDT I HERCEPTIN® continues to be epirubicin and cyclophosphamide followed by docetaxel and trastuzumab funded when trastuzumab is used neoadjuvant or adjuvant therapy for breast cancer using trastuzumab, with pertuzumab for advanced trastuzumab Injectable Breast BRAJTDC I docetaxel and cyclophosphamide breast cancer (BRAVPTRAD, Adjuvant Therapy for Breast Cancer using Trastuzumab Following the trastuzumab Injectable Breast BRAJTR I BRAVPTRAT). HERCEPTIN® is Completion of Chemotherapy (Sequential) funded for treatment started prior adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab injectable Breast BRAJTTW I to February 1st, 2020. trastuzumab palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab injectable Breast trastuzumab (Herceptin®) and docetaxel as first-line treatment for BRAVPTRAD I advanced breast cancer

* denotes change Page 61 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES palliative therapy for metastatic breast cancer using pertuzumab, trastuzumab (cont'd) injectable Breast trastuzumab (Herceptin®), and paclitaxel as first-line treatment for BRAVPTRAT I advanced breast cancer palliative therapy for metastatic breast cancer using trastuzumab and trastuzumab injectable Breast BRAVTCAP I capecitabine single agent therapy for metastatic breast cancer progressing after 1 prior regimens (e.g., taxane) and responding to trastuzumab in trastuzumab injectable Breast BRAVTR I combination with paclitaxel, with paclitaxel and carboplatin, or with vinorelbine Note: Biosimilar trastuzumab combination with 3-weekly vinorelbine as palliative therapy for metastatic (HERZUMA®, TRAZIMERA®) is trastuzumab (cont'd) Injectable Breast BRAVTRVIN I breast cancer funded for treatment started on or treatment of locally advanced breast cancer using doxorubicin and trastuzumab (cont'd) Injectable Breast BRLAACDT I after February 1st, 2020, except cyclophosphamide followed by docetaxel and trastuzumab HERCEPTIN® continues to be Palliative Treatment of Metastatic or Locally Advanced Gastric, funded when trastuzumab is used trastuzumab (cont'd) Injectable Gastrointestinal Gastroesophageal Junction or Esophageal Adenocarcinoma using GIGAVCCT I with pertuzumab for advanced Cisplatin, Capecitabine and Trastuzumab palliative treatment of metastatic or inoperable, locally advanced gastric breast cancer (BRAVPTRAD, trastuzumab (cont'd) Injectable Gastrointestinal or gastroesophageal junction adenocarcinoma using cisplatin, infusional GIGAVCFT I BRAVPTRAT). HERCEPTIN® is fluorouracil and trastuzumab funded for treatment started prior palliative treatment of metastatic or locally advanced gastric, to February 1st, 2020. trastuzumab (cont'd) Injectable Gastrointestinal gastroesophageal junction, or esophageal adenocarcinoma using GIGAVCOXT I capecitabine, oxaliplatin and trastuzumab palliative treatment of metastatic or locally advanced HER-2 positive trastuzumab (cont'd) Injectable Gastrointestinal gastric, gastroesophageal junction, or esophageal adenocarcinoma using GIGAVFFOXT I oxaliplatin, fluorouracil, leucovorin, and trastuzumab continuation of palliative treatment of metastatic or inoperable, locally trastuzumab (cont'd) injectable Gastrointestinal advanced gastric or gastroesophageal junction adenocarcinoma using GIGAVTR I trastuzumab adjuvant therapy for breast cancer using trastuzumab emtansine injectable Breast UBRAJKAD R (KADCYLA) (KADCYLA) trastuzumab emtansine palliative therapy for metastatic breast cancer using trastuzumab injectable Breast UBRAVKAD R (KADCYLA) emtansine (KADCYLA) (SAP) injectable Leukemia & BMT BMTNOS 1 Approval from Health Canada pre-conditioning therapy with treosulfan for pediatric patients at risk for Special Access Programme is treosulfan (SAP) injectable Pediatric busulfan-related toxicity prior to hematopoietic stem cell transplantation R required for each patient for malignant conditions tretinoin (VESANOID®) capsule Leukemia & BMT acute promyelocytic leukemia LKNOS I tretinoin (VESANOID®) first-line induction and consolidation therapy of acute promyelocytic capsule Leukemia & BMT LKATOATRA I (cont'd) leukemia using arsenic trioxide and tretinoin first-line induction and consolidation therapy of acute promyelocytic tretinoin (VESANOID®) capsule Leukemia & BMT LKATOP I leukemia using arsenic trioxide, tretinoin and daunorubicin induction and consolidation therapy of relapsed acute promyelocytic tretinoin (VESANOID®) capsule Leukemia & BMT LKATOR I leukemia using arsenic trioxide and tretinoin (All-Trans Retinoic Acid) treatment of pediatric patients with high-risk neuroblastoma who achieve tretinoin (VESANOID®) capsule Leukemia & BMT a response to prior first-line multi-agent, multimodal therapy using R dinutuximab in combination with sargramostim, aldesleukin and tretinoin Third- or Later-Line Therapy for Advanced Gastroesophageal Carcinoma trifluridine-tipiracil tablet Gastrointestinal UGIGAVTRFT R using Trifluridine-Tipiracil

* denotes change Page 62 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment for locally advanced or metastatic tablet Head and Neck HNOTVAN I using vandetanib treatment of BRAF V600 mutation-positive unresectable or metastatic vemurafenib tablet Skin & Melanoma SMAVVEM I melanoma using vemurafenib treatment of BRAF V600 mutation-positive unresectable or metastatic vemurafenib tablet Skin & Melanoma SMAVVC I melanoma using vemurafenib and cobimetinib treatment of relapsed/refractory chronic lymphocytic leukemia or small venetoclax tablet Lymphoma ULYVENETO R lymphocytic lymphoma using venetoclax treatment of relapsed/refractory chronic lymphocytic leukemia or small venetoclax tablet Lymphoma LYVENETOR I lymphocytic lymphoma using venetoclax and rituximab therapy for transitional cell cancers of the urothelium using methotrexate, vinblastine injectable Genitourinary GUMVAC I vinblastine, doxorubicin and cisplatin consolidation/ salvage treatment for germ cell cancer using vinblastine, vinblastine injectable Genitourinary GUVEIP I cisplatin, ifosfamide and mesna vinblastine injectable Kaposi's Sarcoma therapy for Kaposi's Sarcoma using vinblastine-vincristine KSVB I treatment of Hodgkin's disease with doxorubicin, bleomycin, vinblastine vinblastine injectable Lymphoma LYABVD I and dacarbazine Treatment of Previously Untreated, Stage IV Hodgkin Lymphoma with vinblastine injectable Lymphoma LYAVDBV I Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, vinblastine injectable Lymphoma LYCVPPABO I procarbazine and prednisone vinblastine (cont'd) injectable Lymphoma lymphoma palliative chemotherapy LYPALL I palliative therapy for aggressive fibromatosis using weekly or alternate vinblastine (cont'd) injectable Sarcoma SAMV I week methotrexate and vinblastine intravenously Other tumour site Not Otherwise vinblastine injectable code followed by I Specified ‘NOS’ (e.g. LYNOS) adjuvant lomustine, cisplatin and vincristine in adult high-risk vincristine injectable Neuro-Oncology CNCCV I medulloblastoma or other primitive neuroectodermal tumour modified PCV chemotherapy of brain tumours using procarbazine, vincristine (cont'd) injectable Neuro-Oncology CNMODPCV I lomustine and vincristine therapy for high-risk Gestational Trophoblastic Neoplasia (GTN) using vincristine (cont'd) injectable Gynecology etoposide, methotrexate, leucovorin (folinic acid), dactinomycin, GOTDEMACO I cyclophosphamide and vincristine vincristine (cont'd) injectable Kaposi's sarcoma therapy for Kaposi's Sarcoma using vinblastine-vincristine KSVB I treatment of thymoma/thymic carcinoma with cyclophosphamide, vincristine (cont'd) injectable Lung LUOTCAV I doxorubicin and vincristine treatment of extensive small cell lung cancer with cyclophosphamide, vincristine (cont'd) injectable Lung LUSCCAV I doxorubicin and vincristine treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine vincristine (cont'd) injectable Lymphoma LYCHOP I and prednisone treatment of lymphoma with doxorubicin, cyclophosphamide, vincristine, vincristine (cont'd) injectable Lymphoma LYCHOPR I prednisone and rituximab

* denotes change Page 63 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES central nervous system prophylaxis with high dose methotrexate, CHOP vincristine (cont'd) injectable Lymphoma LYCHOPRMTX I and rituximab in diffuse large B-cell lymphoma treatment of relapsed chronic lymphocytic leukemia using vincristine (cont'd) injectable Lymphoma LYCLLCVPR I cyclophosphamide, vincristine, prednisone and rituximab treatment of Burkitt’s Lymphoma and Leukemia with cyclophosphamide, vincristine (cont'd) injectable Lymphoma LYCODOXMR I vincristine, doxorubicin, methotrexate, leucovorin and rituximab advanced indolent lymphoma using cyclophosphamide, vincristine and vincristine (cont'd) injectable Lymphoma LYCVP I prednisone treatment of Hodgkin's Disease with cyclophosphamide, vinblastine, vincristine (cont'd) injectable Lymphoma LYCVPPABO I procarbazine and prednisone treatment of advanced indolent lymphoma using cyclophosphamide, vincristine (cont'd) injectable Lymphoma LYCVPR I vincristine, prednisone and rituximab treatment of lymphoma with dose-adjusted etoposide, doxorubicin, vincristine (cont'd) injectable Lymphoma vincristine, cyclophosphamide, prednisone and rituximab with intrathecal LYEPOCHR I methotrexate vincristine (cont'd) injectable Lymphoma lymphoma palliative chemotherapy LYPALL I SAIME alternating with SAVAC or SAVACM with filgrastim support at TWO weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s vincristine (cont'd) injectable Sarcoma SAALT2W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma SAIME alternating with SAVAC or SAVACM with filgrastim support at THREE weekly interval for newly diagnosed Ewing's Sarcoma/Ewing’s vincristine (cont'd) injectable Sarcoma SAALT3W I Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma

* denotes change Page 64 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES treatment of sarcomas with vincristine, doxorubicin and vincristine (cont'd) injectable Sarcoma SAVAC I cyclophosphamide Treatment of Sarcomas with Pelvic Primaries or Chemotherapy-Induced vincristine (cont'd) injectable Sarcoma SAVACM I Hematuria using Vincristine, Doxorubicin, Cyclophosphamide and Mesna Adjuvant Therapy for Rhabdomyosarcoma using Vincristine, vincristine (cont'd) injectable Sarcoma SAVDC I Dactinomycin and Cyclophosphamide Other tumour site Not Otherwise vincristine (cont'd) injectable code followed by I Specified ‘NOS’ (e.g. LYNOS) vinorelbine injectable Breast palliative therapy for metastatic breast cancer BRAVNAV I combination with 3-weekly trastuzumab as palliative therapy for vinorelbine injectable Breast BRAVTRVIN I metastatic breast cancer treatment of platinum resistant epithelial ovarian cancer with vinorelbine injectable Gynecology GOOVBEVV I bevacizumab and vinorelbine palliative chemotherapy for re-treatment of ovarian, tubal, and peritoneal vinorelbine injectable Gynecology GOOVVIN I cancer combination with cisplatin as treatment of advanced salivary gland vinorelbine injectable Head and Neck HNSAVNP I cancers with cisplatin and vinorelbine adjuvant cisplatin and vinorelbine following resection of stage I, II and IIIA vinorelbine (cont'd) injectable Lung LUAJNP I non-small cell lung cancer combination with cisplatin as treatment for advanced non-small cell lung vinorelbine (cont'd) injectable Lung LUAVNP I cancer vinorelbine (cont'd) injectable Lung advanced non-small cell lung cancer in elderly patients LUAVVIN I vinorelbine (cont'd) injectable Lung malignant mesothelioma LUMMVIN I pediatric patients treated on the COG protocol AHOD0521 for vinorelbine (cont'd) injectable Pediatric I refractory/recurrent Hodgkin’s disease treatment of pediatric patients with relapsed Hodgkin lymphoma with a vinorelbine (cont'd) injectable Pediatric I combination of ifosfamide, mesna, gemcitabine and vinorelbine (IGEV) treatment of recurrent/refractory rhabdomysarcoma in pediatric patients vinorelbine (cont'd) injectable Pediatric with cyclophosphamide, vinorelbine and temsirolimus on the COG I ARST0921 protocol* capsule Skin & Melanoma treatment of metastatic or locally advanced basal cell carcinoma USMAVVIS R

transarterial radioembolisation of hepatocellular carcinoma with portal yttrium-90 injectable Gastrointestinal GIYTT I venous invasion or T3 tumours, and metastatic neuroendocrine tumours adjuvant therapy for breast cancer in post-menopausal women using zoledronic acid injectable Breast BRAJZOL5 I zoledronic acid adjuvant therapy for breast cancer in post-menopausal women using 3- BRAJZOL2 I monthly zoledronic acid treatment of acute bone pain secondary to breast cancer metastases BRAVZOL I using IV zoledronic acid zoledronic acid injectable Breast treatment of multiple myeloma with zoledronic acid MYZOL I

* denotes change Page 65 of 65 BC Cancer Benefit Drug List September 2021

DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Protocol Code Definitions Transplantation BMT Breast BR Gastrointestinal GI Genitourinary GU Gynecologic GO Head and Neck HN Kaposi’s sarcoma KS Leukemia LK Lung LU Lymphoma LY Miscellaneous Origin MO Myeloma MY Neuro-Oncology CN Ocular OC Primary Unknown PU Sarcoma SA Skin & Melanoma SM

* denotes change